Haemostasis and metastasis: anticoagulants therapeutic potential in ovarian cancer ; Система гемостаза и метастазирование: терапевтический потенциал антикоагулянтов при раке яичников

Συγγραφείς: A. V. Vorobev, V. O. Bitsadze, J. Kh. Khizroeva, A. G. Solopova, D. M. Mamchich, E. D. Mun, D. V. Blinov, J.-C. Gris, I. Elalamy, G. Gerotziafas, P. Van Dreden, A. D. Makatsariya, А. В. Воробьев, В. О. Бицадзе, Д. Х. Хизроева, А. Г. Солопова, Д. М. Мамчич, Э. Д. Мун, Д. В. Блинов, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, П. Ван Дреден, А. Д. Макацария

Συνεισφορές: The authors declare no funding, Авторы заявляют об отсутствии финансовой поддержки

Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 3 (2025); 351-359 ; Акушерство, Гинекология и Репродукция; Vol 19, No 3 (2025); 351-359 ; 2500-3194 ; 2313-7347

Θεματικοί όροι: противоопухолевый эффект, АСТ, ovarian cancer, OC, relapse, metastasis, venous thromboembolism, direct oral anticoagulants, thrombin, fibrin matrix, thrombosis, tumor invasion, antitumor effect, АКТ, рак яичников, РЯ, рецидив, метастазирование, венозная тромбоэмболия, прямые оральные антикоагулянты, тромбин, фибриновый матрикс, тромбоз, инвазия опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2493/1343; Sung H., Ferlay J., Siegel R.L. at al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660; Бредихин Р.А., Ахметзянов Р.В., Хайруллин Р.Н. Расширение возможностей лечения и профилактики венозных тромбоэмболических осложнений у пациентов с онкологическими заболеваниями. Роль пероральных антикоагулянтов. Клиницист. 2022;16(2):17–26. https://doi.org/10.17650/1818-8338-2022-16-2-К667.; Mulder F.I., Horváth-Puhó E., van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–69. https://doi.org/10.1182/blood.2020007338.; Streiff M.B. Thrombosis in the setting of cancer. Hematology Am Soc Hematol Educ Program. 2016;2016(1):196–205. https://doi.org/10.1182/asheducation-2016.1.196.; Guo J., Gao Y., Gong Z. et al. Plasma D-dimer level correlates with age, metastasis, recurrence, tumor-node-metastasis classification (TNM), and treatment of non-small-cell lung cancer (NSCLC) patients. Biomed Res Int. 2021;2021:9623571. https://doi.org/10.1155/2021/9623571.; Hisada Y., Mackman N. Tissue factor and cancer: regulation, tumor growth and metastasis. Semin Thromb Hemost. 2019;45(4):385–95. https://doi.org/10.1055/s-0039-1687894.; Zhao B., Wu M., Hu Z. et al. A novel oncotherapy strategy: direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. Br J Pharmacol. 2022;179(22):5056–73. https://doi.org/10.1111/bph.15384.; Hisada Y., Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–506. https://doi.org/10.1182/blood-2017-03-743211.; Слуханчук Е.В., Бицадзе В.О., Хизроева Д.Х. и др. Тромбоциты, тромбовоспаление и онкологический процесс. Акушерство, Гинекология и Репродукция. 2021;15(6):755–76. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.274.; Stone R.L., Nick A.M., McNeish I.A. et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8. https://doi.org/10.1056/NEJMoa1110352.; Zhou L., Zhang Z., Tian Y. et al. The critical role of platelet in cancer progression and metastasis. Eur J Med Res. 2023;28(1):385. https://doi.org/10.1186/s40001-023-01342-w.; Miyazaki M., Nakabo A., Nagano Y. et al. Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis. Cancer Lett. 2023;553:215983. https://doi.org/10.1016/j.canlet.2022.215983.; Cohen A.T., Hamilton M., Mitchell S.A. et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thrombo-embolism: systematic review and network meta-analysis. PLoS One. 2015;10(12):e0144856. https://doi.org/10.1371/journal.pone.0144856.; Farge D., Frere C., Connors J.M. et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. https://doi.org/10.1016/S1470-2045(22)00160-7.; Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol. 2023;41(16):3063–71. https://doi.org/10.1200/JCO.23.00294.; Kurube I., Ambari E., Iskandar T. et al. Factors associated with recurrence of epithelial ovarian cancer In RSUP Dr. Kariadi Semarang. DIMJ. 2022;3(2):74–80. https://doi.org/10.14710/dimj.v3i2.15448.; Joy J., Kumar J., Kumar S., Arshad M. Clinical profiles and survival outcomes of patients with relapsed ovarian cancer: a single-center study. Cureus. 2024;16(11):e74724. https://doi.org/10.7759/cureus.74724.; Al-Azzawi H.M.A., Hamza S.A., Paolini R. et al. Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis. Front Oral Health. 2024;5:1495942. https://doi.org/10.3389/froh.2024.1495942.; Najidh S., Versteeg H.H., Buijs J.T. A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models. Thromb Res. 2020;187:18–27. https://doi.org/10.1016/j.thromres.2019.12.022.; https://www.gynecology.su/jour/article/view/2493

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/2493
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.644

Recurrent thrombosis in malignant neoplasms: clinical significance of long-term anticoagulant prophylaxis ; Рецидивирующие тромбозы при злокачественных новообразованиях: клиническая значимость длительной антикоагулянтной профилактики

Συγγραφείς: A. V. Vorobеv, A. G. Solopova, N. V. Lomakin, V. O. Bitsadze, M. V. Kim, K. N. Grigoreva, K. V. Gadatskaia, V. N. Galkin, D. O. Utkin, I. Elalamy, A. D. Makatsariya, А. В. Воробьев, А. Г. Солопова, Н. В. Ломакин, В. О. Бицадзе, М. В. Ким, К. Н. Григорьева, К. В. Гадацкая, В. Н. Галкин, Д. О. Уткин, И. Элалами, А. Д. Макацария

Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 2 (2025); 168-179 ; Акушерство, Гинекология и Репродукция; Vol 19, No 2 (2025); 168-179 ; 2500-3194 ; 2313-7347

Θεματικοί όροι: прямые оральные антикоагулянты, VTE, recurrent thrombosis, ovarian cancer, ОС, anticoagulant therapy, АСТ, long-term prophylaxis, deep vein thrombosis, pulmonary embolism, Khorana scale, Vienna-CATS scale, Tic-Onco scale, genetic thrombophilia, D-dimer, direct oral anticoagulants, ВТЭ, рецидивирующий тромбоз, рак яичников, РЯ, антикоагулянтная терапия, АКТ, длительная профилактика, тромбоз глубоких вен, тромбоэмболия легочной артерии, шкала Khorana, шкала Vienna-CATS, шкала Tic-Onco, генетическая тромбофилия, D-димер

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2426/1318; Becattini C., Di Nisio M., Franco L. et al. Treatment of venous thromboembolism in cancer patients: the dark side of the moon. Cancer Treat Rev. 2021;96:102190. https://doi.org/10.1016/j.ctrv.2021.102190.; Cohen A., Lim C.S., Davies A.H. Venous thromboembolism in gynecological malignancy. Int J Gynecol Cancer. 2017;27(9):1970–8. https://doi.org/10.1097/IGC.0000000000001111.; Salinaro J.R., McQuillen K., Stemple M. et al. Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2020;30(4):491–7. https://doi.org/10.1136/ijgc-2019-000980.; Moufarrij S., Sassine D., Basaran D., Jewell E.L. Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: a literature review. Gynecol Oncol. 2023;170:167–71. https://doi.org/10.1016/j.ygyno.2023.01.012.; Marques I.S., Tavares V., Savva-Bordalo J. et al. Long non-coding RNAs: bridging cancer-associated thrombosis and clinical outcome of ovarian cancer patients. Int J Mol Sci. 2023;25(1):140. https://doi.org/10.3390/ijms25010140.; Дерябина В.А., Матухин В.И., Рухляда Н.Н. и др. Риски тромботических осложнений у пациентов с раком яичников и некоторые аспекты безопасности применения антифибринолитических гемостатических средств. Акушерство и гинекология. 2023;(10):60–9. https://doi.org/10.18565/aig.2023.107.; Han L., Chen Y., Zheng A., Chen H. Incidence and risk factors for venous thromboembolism in patients with ovarian cancer during neoadjuvant chemotherapy: a meta-analysis. Am J Cancer Res. 2023;13(5):2126–34.; Григорьева К.Н., Гашимова Н.Р., Цибизова В.И. Коррекция гемостаза в лечении и реабилитации пациентов с COVID-19. Реабилитология. 2023;1(1):49–59. https://doi.org/10.17749/2949-5873/rehabil.2023.3.; Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost. 2019;45(4):342–7. https://doi.org/10.1055/s-0039-1687890.; Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7. https://doi.org/10.1182/blood-2007-10-116327.; Khorana A.A., Mackman N., Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. https://doi.org/10.1038/s41572-022-00336-y.; Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24): 377–82. https://doi.org/10.1182/blood-2010-02-270116.; Martin A.J.M., Ortega I., Font C. et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(8):1056–61. https://doi.org/10.1038/s41416-018-0027-8.; Шульман C., Макацария А.Д., Воробьев А.В. и др. Злокачественные новообразования и тромбозы. Акушерство и гинекология. 2019;(7):14–23. https://doi.org/10.18565/aig.2019.7.14-23.; Петриков А.С., Вавилова Т.В., Варданян А.В. и др. Первичная профилактика венозных тромбоэмболических осложнений низкомолекулярными гепаринами у хирургических пациентов – 2024: резолюция Совета экспертов. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2024;17(2):251–78. https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.250.; Fujisaki T., Sueta D., Yamamoto E. et al. Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis. JACC CardioOncol. 2024;6(1):99–113. https://doi.org/10.1016/j.jaccao.2023.10.009.; Talmor-Barkan Y., Yacovzada N.-S., Rossman H. et al. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. Eur Heart J Cardiovasc Pharmacother. 2022;9(1):26–37. https://doi.org/10.1093/ehjcvp/pvac063.; Cohen A.T., Hamilton M., Mitchell S.A. et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One. 2015;10(12):e0144856. https://doi.org/10.1371/journal.pone.0144856.; Farge D., Frere C., Connors J.M. et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. https://doi.org/10.1016/S1470-2045(22)00160-7.; Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update. J Clin Oncol. 2023;41(16):3063–71. https://doi.org/10.1200/JCO.23.00294.; Barca-Hernando M., Lopez-Ruz S., Marin-Romero S. et al. Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism. Front Cardiovasc Med. 2023;10:1118385. https://doi.org/10.3389/fcvm.2023.1118385.; Lanting V.R., Takada T., Bosch F.T.M. et al. Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thromb Haemost. 2024 Oct 16. https://doi.org/10.1055/a-2418-3960.; Khorana A.A., McCrae K.R., Milentijevic D. et al. Duration of anticoagulant therapy and VTE recurrence in patients with cancer. Support Care Cancer. 2019;27(10):3833–40. https://doi.org/10.1007/s00520-019-4661-3.; Dave H.M., Khorana A.A. Management of venous thromboembolism in patients with active cancer. Cleve Clin J Med. 2024;91(2):109–17. https://doi.org/10.3949/ccjm.91a.23017.; Moik F., Colling M., Mah? I. et al. Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost. 2022;20(3):619–34. https://doi.org/10.1111/jth.15599.; Хизроева Д.Х., Асланова З.Д., Солопова А.Г. и др. Роль внеклеточных ловушек нейтрофилов в прогрессии рака и развитии тромбозов. Акушерство, Гинекология и Репродукция. 2024;18(1):55–67. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.475.; Воробьев А.В., Эйнуллаева С.Э., Бородулин А.С. и др. Влияние COVID-19 на тромботические осложнения у онкологических больных. Акушерство, Гинекология и Репродукция. 2024;18(3):286–99. Https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.519.; Воробьев А.В., Солопова А.Г., Бицадзе В.О. и др. Сравнение эффективности шкал Khorana, Vienna CATS, TiC-Onco и соотношения vWF/ADAMTS13 в выявлении высокого риска тромботических осложнений у больных злокачественными новообразованиями. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2025;18(1): 71–9. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.308.; Bertoletti L., Girard P., Elias A. et al., INNOVTE CAT Working Group. Recurrent venous thromboembolism in anticoagulated cancer patients: diagnosis and treatment. Arch Cardiovasc Dis. 2024;117(1):84–93. https://doi.org/10.1016/j.acvd.2023.11.006.; Федоткина Ю.А., Панченко Е.П. Современные подходы к профилактике венозных тромбоэмболических осложнений у пациентов с активным раком. Атеротромбоз. 2022;12(2):44–62. https://doi.org/10.21518/2307-1109-2022-12-2-44-62.; Patell R., Hsu C., Shi M. et al. Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer. Haematologica. 2024;109(6):1849–56. https://doi.org/10.3324/haematol.2023.284192.; https://www.gynecology.su/jour/article/view/2426

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/2426
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.629

Atrial fibrillation and multimorbidity: How to choose the perfect direct oral anticoagulant? ; Фибрилляция предсердий и полиморбидность: как выбрать идеальный прямой оральный антикоагулянт?

Συγγραφείς: O. D. Ostroumova, A. V. Dubinina, S. S. Telkova, A. I. Kochetkov, N. E. Gavrilova, E. Yu. Ebzeeva, A. V. Arablinskiy, O. A. Milovanova, О. Д. Остроумова, А. В. Дубинина, С. С. Телкова, А. И. Кочетков, Н. Е. Гаврилова, Е. Ю. Эбзеева, А. В. Араблинский, О. А. Милованова

Πηγή: Meditsinskiy sovet = Medical Council; № 16 (2024); 54-62 ; Медицинский Совет; № 16 (2024); 54-62 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: апиксабан, coronary artery disease, chronic kidney disease, anemia, multimorbidity, direct oral anticoagulants, apixaban, хроническая болезнь почек, анемия, прямые оральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8612/7560; Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. https://doi.org/10.1177/1747493019897870.; Kavousi M. Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men. Front Cardiovasc Med. 2020;7:3. https://doi.org/10.3389/fcvm.2020.00003.; Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020;127(1):4–20. https://doi.org/10.1161/CIRCRESAHA.120.316340.; Ohlrogge AH, Brederecke J, Schnabel RB. Global Burden of Atrial Fibrillation and Flutter by National Income: Results From the Global Burden of Disease 2019 Database. J Am Heart Assoc. 2023;12(17):e030438. https://doi.org/10.1161/JAHA.123.030438.; Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046. https://doi.org/10.1161/01.CIR.0000140263.20897.42.; Ардашев АВ, Беленков ЮН, Матюкевич МЧ, Снежицкий ВА. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021;61(2):91–98. https://doi.org/10.18087/cardio.2021.2.n1348.; Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–952. https://doi.org/10.1161/01.cir.98.10.946.; Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.; Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125. https://doi.org/10.1161/CIRCULATIONAHA.105.595140.; Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554. https://doi.org/10.1212/01.wnl.0000267275.68538.8d.; Forman DE, Goyette RE. Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks. Clin Appl Thromb Hemost. 2014;20(1):5–15. https://doi.org/10.1177/1076029613492010.; Van den Bussche H, Koller D, Kolonko T, Hansen H, Wegscheider K, Glaeske G et al. Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based crosssectional study in Germany. BMC Public Health. 2011;11:101. https://doi.org/10.1186/1471-2458-11-101.; LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, Nelson WW. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62. https://doi.org/10.1177/1753944712464101.; Kozieł M, Teutsch C, Halperin JL, Rothman KJ, Diener HC, Ma CS et al. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE. 2021;16(4):e0249524. https://doi.org/10.1371/journal.pone.0249524.; Vanbeselaere V, Truyers C, Elli S, Buntinx F, De Witte H, Degryse J et al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord. 2016;16:61. https://doi.org/10.1186/s12872-016-0235-1.; Van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410–1416. https://doi.org/10.1161/STROKEAHA.108.526988.; Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. https://doi.org/10.1093/eurheartj/ehy136.; Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31(8):967–975. https://doi.org/10.1093/eurheartj/ehn599.; Fumagalli S, Said SA, Laroche C, Gabbai D, Boni S, Marchionni N et al. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):172–179. https://doi.org/10.1093/ehjcvp/pvx037.; Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102–1107. https://doi.org/10.1016/j.ahj.2010.03.027.; Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, Lerma EV. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):173–181. https://doi.org/10.2215/CJN.03170509.; Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 2012;81(5):469–476. https://doi.org/10.1038/ki.2011.416.; Дружилов МА, Кузнецова ТЮ, Дружилова ОЮ, Арустамова УД, Гаврилов ДВ, Гусев АВ. Фибрилляция предсердий и хроническая болезнь почек: основные клинические характеристики пациентов в отдельных субъектах Российской Федерации. Кардиоваскулярная терапия и профилактика. 2023;22(4):3544. https://doi.org/10.15829/1728-8800-2023-3544.; Yao RJR, Holmes DN, Andrade JG, Levin A, Piccini JP, Fordyce CB. Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II. J Am Heart Assoc. 2023;12(6):e026605. https://doi.org/10.1161/JAHA.122.026605.; Cha MJ, Cho Y, Oh IY, Choi EK, Oh S. Validation of Conventional Thromboembolic Risk Factors in a Korean Atrial Fibrillation Population – Suggestion for a Novel Scoring System, CHA2DS2-VAK. Circ J. 2018;82(12):2970–2975. https://doi.org/10.1253/circj.CJ-18-0218.; Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Lin YJ et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209–1215. https://doi.org/10.1038/ki.2014.393.; Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc. 2012;1(4):e002097. https://doi.org/10.1161/JAHA.112.002097.; Arnson Y, Hoshen M, Berliner-Sendrey A, Reges O, Balicer R, Leibowitz M et al. Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Cardiology. 2020;145(3):178–186. https://doi.org/10.1159/000504877.; Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L et al. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD – AF Registry. J Am Heart Assoc. 2019;8(3):e010510. https://doi.org/10.1161/JAHA.118.010510.; Аракелян МГ, Бокерия ЛА, Васильева ЕЮ, Голицын СП, Голухова ЕЗ, Горев МВ и др. Фибрилляция и трепетание предсердий у взрослых: клинические рекомендации. М.; 2020. 152 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/382_1.; Bonde AN, Lip GY, Kamper AL, Fosbøl EL, Staerk L, Carlson N et al. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke. 2016;47(11):2707–2713. https://doi.org/10.1161/STROKEAHA.116.014422.; Sitticharoenchai P, Takkavatakarn K, Boonyaratavej S, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. Non-Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non-Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis. J Am Heart Assoc. 2021;10(7):e019609. https://doi.org/10.1161/JAHA.120.019609.; Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961–970. https://doi.org/10.1161/CIRCULATIONAHA.113.003628.; Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821–2830. https://doi.org/10.1093/eurheartj/ehs274.; Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G et al. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017;135(10):1001–1003. https://doi.org/10.1161/CIRCULATIONAHA.116.024666.; Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24–36. https://doi.org/10.1161/CIRCULATIONAHA.116.022361.; Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–339. https://doi.org/10.1016/j.ahj.2009.07.035.; Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451–460. https://doi.org/10.1001/jamacardio.2016.1170.; Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020;141(17):1384–1392. https://doi.org/10.1161/CIRCULATIONAHA.119.044059.; Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease – Double trouble. Adv Med Sci. 2018;63(1):30–35. https://doi.org/10.1016/j.advms.2017.06.005.; Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–114. https://doi.org/10.1001/jamainternmed.2013.11912.; Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038–1045. https://doi.org/10.1093/eurheartj/ehn579.; Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008;155(2):361–368. https://doi.org/10.1016/j.ahj.2007.09.003.; Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103(1):13–28. https://doi.org/10.1160/TH09-08-0580.; Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Roger VL. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;123(19):2094–2100. https://doi.org/10.1161/CIRCULATIONAHA.110.990192.; Alasady M, Abhayaratna WP, Leong DP, Lim HS, Abed HS, Brooks AG et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011;8(7):955–960. https://doi.org/10.1016/j.hrthm.2011.02.016.; Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, Oldgren J. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102(12):926–933. https://doi.org/10.1136/heartjnl-2015-308678.; Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393.; Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215–220. https://doi.org/10.1016/j.ijcard.2013.10.062.; Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665–1671. https://doi.org/10.1056/NEJM199812033392303.; Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–1912. https://doi.org/10.1016/S0140-6736(06)68845-4.; Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967–1974. https://doi.org/10.1016/S0140-6736(09)61751-7.; Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–1441. https://doi.org/10.1001/archinternmed.2010.271.; Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509–1524. https://doi.org/10.1056/NEJMoa1817083.; Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. https://doi.org/10.1056/NEJMoa1611594.; Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561.; Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513–1524. https://doi.org/10.1056/NEJMoa1708454.; Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost. 2015;13(5):699–707. https://doi.org/10.1111/jth.12874.; Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2017;185:140–149. https://doi.org/10.1016/j.ahj.2016.12.008.; Tu SJ, Hanna-Rivero N, Elliott AD, Clarke N, Huang S, Pitman BM et al. Associations of anemia with stroke, bleeding, and mortality in atrial fibrillation: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2021;32(3):686–694. https://doi.org/10.1111/jce.14898.; Bonde AN, Blanche P, Staerk L, Gerds TA, Gundlund A, Gislason G et al. Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. Eur Heart J. 2019;40(46):3782–3790. https://doi.org/10.1093/eurheartj/ehz155.; Puurunen M, Kiviniemi T, Nammas W, Schlitt A, Rubboli A, Nyman K et al. Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. BMJ Open. 2014;4(5):e004700. https://doi.org/10.1136/bmjopen-2013-004700.; Alboni P, Stucci N, Messop AC. Il trattamento anticoagulante nei pazienti con fibrillazione atriale non valvolare e anemia cronica: ancora zone grigie. G Ital Cardiol (Rome). 2021;22(4):311–318. https://doi.org/10.1714/3574.35577.; Tanaka N, Inoue K, Okada M, Sakata Y, Akao M, Yamashita T et al. Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis. Int J Cardiol Heart Vasc. 2022;40:100994. https://doi.org/10.1016/j.ijcha.2022.100994.; Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52–60. https://doi.org/10.1001/jama.2015.7008.; Fan J, Sun Z, Yu C, Guo Y, Pei P, Yang L et al. Multimorbidity patterns and association with mortality in 0.5 million Chinese adults. Chin Med J (Engl). 2022;135(6):648–657. https://doi.org/10.1097/CM9.0000000000001985.; Kato D, Kawachi I, Saito J, Kondo N. Complex multimorbidity and mortality in Japan: a prospective propensity-matched cohort study. BMJ Open. 2021;11(8):e046749. https://doi.org/10.1136/bmjopen-2020-046749.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/8612
https://doi.org/10.21518/ms2024-388

Treatment of Cancer-Associated Venous thrombosis with Direct Oral Anticoagulants

Πηγή: Кардиология в Беларуси. :100-114

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, treatment, прямые оральные антикоагулянты, лечение, злокачественные опухоли, malignant tumors, direct oral anticoagulants, тромбоз глубоких вен, deep vein thrombosis, 3. Good health

Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants ; Тромбоз левого желудочка: состояние проблемы и место прямых оральных антикоагулянтов

Συγγραφείς: A. D. Aga, A. A. Sokolova, D. A. Napalkov, А. Д. Ага, А. А. Соколова, Д. А. Напалков

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 6 (2022); 727-733 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 6 (2022); 727-733 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: кардиомиопатия, warfarin, anticoagulants, left ventricular thrombosis, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, myocardial infarction, cardiomyopathy, варфарин, антикоагулянты, тромбоз левого желудочка, прямые оральные антикоагулянты, апиксабан, ривароксабан, дабигатран, инфаркт миокарда

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2862/2388; Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. DOI:10.1093/eurheartj/ehx393.; Кропачева Е.С. Внутрисердечный тромбоз: частота, факторы риска и место пероральных антикоагулянтов в лечении. Атеротромбоз. 2020;(1):134-52. DOI:10.21518/2307-1109-2020-1-134-152.; Habash F, Vallurupalli S. Challenges in management of left ventricular thrombus. Ther Adv Cardiovasc Dis. 2017;11(8):203-13. DOI:10.1177/1753944717711139.; Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in the primary PCI era: A systematic review and meta-analysis. Int J Cardiol. 2016;221:554-9. DOI:10.1016/j.ijcard.2016.07.069.; Pöss J, Desch S, Eitel C, et al. Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study. Circ Cardiovasc Imaging. 2015;8(10):e003417. DOI:10.1161/CIRCIMAGING.115.003417.; Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart. 2012;98(23):1743-9. DOI:10.1136/heartjnl-2012-301962.; Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. Cardiac Magnetic Resonance Imaging for the Diagnosis of Left Ventricular Thrombus: A Systematic Review. Can J Cardiol. 2015;31(6):785-91. DOI:10.1016/j.cjca.2015.01.011.; Weinsaft JW, Kim J, Medicherla CB, et al. A Novel Imaging Algorithm for Post Myocardial Infarction Left Ventricular Thrombus – Regional LV Function on Echocardiography as a Gatekeeper for Thrombus Evaluation by Delayed Enhancement Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2016;9(5):505-15. DOI:10.1016/j.jcmg.2015.06.017.; Dinesh Kumar US, Shetty SP, Sujay KR, Wali M. Left ventricular mass: A tumor or a thrombus diagnostic dilemma. Ann Card Anaesth. 2016;19(4):728-32. DOI:10.4103/0971-9784.191551.; Lemaître AI, Picard F, Maurin V et al. Clinical profile and midterm prognosis of left ventricular thrombus in heart failure. ESC Heart Fail. 2021;8(2):1333-41. DOI:10.1002/ehf2.13211.; Hamada M. Left Ventricular Thrombus in Hypertrophic Cardiomyopathy. Intern Med Tokyo Jpn. 2019;58(4):465-7. DOI:10.2169/internalmedicine.1646-18.; Becker RC, Owens AP, Sadayappan S. Tissue-Level Inflammation and Ventricular Remodeling in Hypertrophic Cardiomyopathy. J Thromb Thrombolysis. 2020;49(2):177-83. DOI:10.1007/s11239-019-02026-1.; Herath HMMTB, Pahalagamage SP, Lindsay LC, et al. Takotsubo cardiomyopathy complicated with apical thrombus formation on first day of the illness: a case report and literature review. BMC Cardiovasc Disord. 2017;17(1):176. DOI:10.1186/s12872-017-0616-0.; Ding KJ, Cammann VL, Szawan KA, et al. Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome: Insights From the International Takotsubo Registry. Arterioscler Thromb Vasc Biol. 2020;40(1):279-87. DOI:10.1161/ATVBAHA.119.313491.; Шилова А.С., Шмоткина А.О., Яфарова А.А., Гиляров М.Ю. Синдром такоцубо: современные представления о патогенезе, распространенности и прогнозе. Рациональная Фармакотерапия В Кардиологии. 2018;14(4):598-604. DOI:10.20996/1819-6446-201814-4-598-604.; Chimenti C, Lavalle C, Magnocavallo M, et al. A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. ESC Heart Fail. 2021;9(1):241-50. DOI:10.1002/ehf2.13694.; Pitta S, Thatai D, Afonso L. Thromboembolic complications of left ventricular noncompaction: case report and brief review of the literature. J Clin Ultrasound JCU. 2007;35(8):465-8. DOI:10.1002/jcu.20349.; Bakalli A, Georgievska-Ismail L, Koçinaj D, et al. Left ventricular and left atrial thrombi in sinus rhythm patients with dilated ischemic cardiomyopathy. Med Arch Sarajevo Bosnia Herzeg. 2012;66(3):155-8. DOI:10.5455/medarh.2012.66.155-158.; Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020;136(4):381-3. DOI:10.1182/blood.2020007335.; Giustino G, Pinney SP, Lala A, et al. Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. J Am Coll Cardiol. 2020;76(17):2011-23. DOI:10.1016/j.jacc.2020.08.059.; Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020;76(5):533-46. DOI:10.1016/j.jacc.2020.06.007.; Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-58. DOI:10.1038/s41569-020-0413-9.; Diaz-Arocutipa C, Torres-Valencia J, Saucedo-Chinchay J, Cuevas C. ST-segment elevation in patients with COVID-19: a systematic review. J Thromb Thrombolysis. 2021;52(3):738-45. DOI:10.1007/s11239-021-02411-9.; Azevedo RB, Botelho BG, Hollanda JVG de, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11. DOI:10.1038/s41371-020-0387-4.; Fenton M, Siddavaram S, Sugihara C, Husain S. Lessons of the month 3: ST-elevation myocardial infarction and left ventricular thrombus formation: an arterial thrombotic complication of severe COVID-19 infection. Clin Med Lond Engl. 2020;20(4):437-9. DOI:10.7861/clinmed.2020-0266.; Materna O, Koubský K, Pádr R, Janoušek J. Major left ventricular thrombi in an adolescent with COVID19-associated inflammatory syndrome. Eur Heart J. 2021;42(33):3207. DOI:10.1093/eurheartj/ehab165.; O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140. DOI:10.1016/j.jacc.2012.11.019.; Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S. DOI:10.1378/chest.1412S3.; Abdelnabi M, Saleh Y, Fareed A, et al. Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial). J Am Coll Cardiol. 2021;77(12):1590-2. DOI:10.1016/j.jacc.2021.01.049.; Alcalai R, Butnaru A, Moravsky G, et al. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus, A Prospective Multicenter Randomized Clinical Trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):660-7. DOI:10.1093/ehjcvp/pvab057.; Isa W Y W, Hwong N, Mohamed Yusof AK, et al. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus: A Pilot Prospective Randomized Outcome Blinded Study Investigating Size Reduction or Resolution of Left Ventricular Thrombus. J Clin Prev Cardiol. 2020;9(4):150-4. DOI:10.4103/JCPC.JCPC_41_20.; Bass ME, Kiser TH, Page RL, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021;52(2):517-22. DOI:10.1007/s11239-020-02371-6.; Cochran JM, Jia X, Kaczmarek J, et al. Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective, Multicenter Study and Meta-Analysis of Existing Data. J Cardiovasc Pharmacol Ther. 2021;26(2):173-8. DOI:10.1177/1074248420967644.; Daher J, Da Costa A, Hilaire C, et al. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. Clin Drug Investig. 2020;40(4):343- 53. DOI:10.1007/s40261-020-00898-3.; Durrer-Ariyakuddy K, Moccetti F, Stämpfli S. Direct oral anticoagulants versus vitamin K antagonists for treatment of left ventricular thrombus – insights from multicenter registry. Cardiovasc Med. 2019;22:P27. DOI:10.4414/cvm.2019.02052.; Gama F, Freitas P, Trabulo M, et al. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J. 2019;40(Suppl_1):ehz747.0118. DOI:10.1093/eurheartj/ehz747.0118.; Guddeti RR, Anwar M, Walters RW, et al. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020;133(12):1488-91. DOI:10.1016/j.amjmed.2020.05.025.; Iqbal H, Straw S, Craven TP, et al. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail. 2020;7(5):2032-41. DOI:10.1002/ehf2.12718.; Jaidka A, Zhu T, Lavi S, Johri A. Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction Can J Cardiol. 2018;34(10):S143. DOI:10.1016/j.cjca.2018.07.194.; Willeford A, Zhu W, Stevens C, Thomas IC. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus. Ann Pharmacother. 2021;55(7):839-45. DOI:10.1177/1060028020975111.; Xu Z, Li X, Li X, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus. Ann Palliat Med. 2021;10(9):9427-34. DOI:10.21037/apm-21-1683.; Yunis A, Seese L, Stearns B, et al. Direct oral anticoagulants are effective therapy in treating left ventricular thrombi. J Am Coll Cardiol. 2020;75(11):948. DOI:10.1016/S0735-1097(20)31575-8.; Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):398-404. DOI:10.1093/ehjcvp/pvaa096.; Ali Z, Isom N, Dalia T, et al. Direct oral anticoagulant use in left ventricular thrombus. Thromb J. 2020;18:29. DOI:10.1186/s12959-020-00242-x.; Saleh Y, Al-Abcha A, Abdelkarim O, et al. Meta-Analysis Investigating the Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi. Am J Cardiol. 2021;150:126- 8. DOI:10.1016/j.amjcard.2021.03.032.; Saleiro C, Lopes J, De Campos D, et al. Left Ventricular Thrombus Therapy With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review and Meta-Analysis. J Cardiovasc Pharmacol Ther. 2021;26(3):233-43. DOI:10.1177/1074248420977567.; Li S, Deng Y, Tong Y, et al. Assessment of non-vitamin K antagonist oral anticoagulants for the management of left ventricular thrombus. Clin Cardiol. 2021;44(6):754-60. DOI:10.1002/clc.23553.; Michael F, Natt N, Shurrab M. Direct Oral Anticoagulants vs Vitamin K Antagonists in Left Ventricular Thrombi: A Systematic Review and Meta-analysis. CJC Open. 2021;3(9):1169-81. DOI:10.1016/j.cjco.2021.04.007.; Trongtorsak A, Thangjui S, Kewcharoen J, et al. Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis. Acta Cardiol. 2021;76(9):933-42. DOI:10.1080/00015385.2020.1858538.; Kajy M, Shokr M, Ramappa P. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature. Am J Ther. 2020;27(6):e584-90. DOI:10.1097/MJT.0000000000000937.; Tomasoni D, Sciatti E, Bonelli A, et al. Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. J Cardiovasc Pharmacol. 2020;75(6):530-4. DOI:10.1097/FJC.0000000000000826.; Abdelaziz HK, Megaly M, Debski M, et al. Meta-Analysis Comparing Direct Oral Anticoagulants to Vitamin K Antagonists for The Management of Left Ventricular Thrombus. Expert Rev Cardiovasc Ther. 2021;19(5):427-32. DOI:10.1080/14779072.2021.1915134.; Chen R, Zhou J, Liu C, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus: a systematic review and meta-analysis. Pol Arch Intern Med. 2021;131(5):429- 38. DOI:10.20452/pamw.15923.; Kido K, Ghaffar YA, Lee JC, et al. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. PloS One. 2021;16(6):e0252549. DOI:10.1371/journal.pone.0252549.; Robinson AA, Trankle CR, Eubanks G, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020;5(6):685-92. DOI:10.1001/jamacardio.2020.0652.; Lim CW, Mamat RM, Hishammudin IA, et al. Left Ventricular Thrombus: Patient Characteristics and Treatment from a Single Tertiary Centre’s Experience. Int J Cardiol. 2019;297:20-1. DOI:10.1016/j.ijcard.2019.11.056.; Degheim G, Berry A, Zughaib M. Off label use of direct oral anticoagulants for left ventricular thrombus. Is it appropriate? Am J Cardiovasc Dis. 2017;7(5):98-101.; Moey MYY, Tomdio AN, Achike O, Kabirdas D. Large Left Ventricular Thrombus as a Cause of Recurrent Cardioembolic Stroke While on Dabigatran. CASE Cardiovasc Imaging Case Rep. 2018;2(5):222-4. DOI:10.1016/j.case.2018.04.008.; Kaya A, Hayıroğlu Mİ, Keskin M, et al. Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy. Turk Kardiyol Dernegi Arsivi Turk Kardiyol Derneginin Yayin Organidir. 2016;44(4):335-7. DOI:10.5543/tkda.2015.68054.; Kaku B. Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. J Med Case Reports. 2013;7:238. DOI:10.1186/1752-1947-7-238.; Elikowski W, Małek-Elikowska M, Fertała N, et al. Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. Pol Merkur Lek Organ Pol Tow Lek. 2018;44(259): 19-22.; Sun H, Zhao Q, Wang Y, et al. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy. Medicine (Baltimore). 2018;97(4):e9670. DOI:10.1097/MD.0000000000009670.; Bahmaid RA, Ammar S, Al-Subaie S, et al. Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus—A case series and literature review. JRSM Cardiovasc Dis. 2019;8: 2048004019839548. DOI:10.1177/2048004019839548.; Shokr M, Ahmed A, Abubakar H, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature. Clin Case Rep. 2018;7(1):135-42. DOI:10.1002/ccr3.1917.; Smetana KS, Dunne J, Parrott K, et al. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis. 2017;44(4):519-24. DOI:10.1007/s11239-017-1560-7.; Verma B, Singh A, Kumar M. Use of dabigatran for treatment of left ventricular thrombus: A tertiary care center experience. J Fam Med Prim Care. 2019;8(8):2656-60. DOI:10.4103/jfmpc.jfmpc_459_19.; https://www.rpcardio.com/jour/article/view/2862

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2862
https://doi.org/10.20996/1819-6446-2022-12-10

Тромбоэмболические осложнения

Συγγραφείς: О. В. Сомонова, Э. А. Антух, А. В. Варданян, Е. Г. Громова, Б. И. Долгушин, А. Л. Елизарова, Д. Д. Сакаева, В. Ю. Сельчук, А. А. Трякин, В. А. Черкасов

Πηγή: Malignant tumours; Том 13, № 3s2-2 (2023); 167-178 ; Злокачественные опухоли; Том 13, № 3s2-2 (2023); 167-178 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: прямые оральные антикоагулянты, тромбоэмболические осложнения, низкомолекулярные гепарины, гепарин натрия, фондапаринукс

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1254/888; https://www.malignanttumors.org/jour/article/view/1254

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1254
https://doi.org/10.18027/2224-5057-2023-13-3s2-2-167-178

Thrombodynamics Test in Assessing the Risk of Thrombus Formation in Patients with Atrial Fibrillation Taking Direct Oral Anticoagulants ; Тест «Тромбодинамика» в оценке риска тромбообразования у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты

Συγγραφείς: Z. A. Gebekova, I. I. Ivanov, A. Asambayeva, A. I. Skripka, A. A. Sokolova, D. A. Napalkov, T. A. Vuimo, З. А. Гебекова, И. И. Иванов, А. Асамбаева, А. И. Скрипка, А. А. Соколова, Д. А. Напалков, Т. А. Вуймо

Συνεισφορές: The study was performed with the support of the Sechenov University, Pirogov Russian National Research Medical University, Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology., Исследование проведено при поддержке Сеченовского Университета, Российского национального исследовательского медицинского университета имени Н.И. Пирогова, Национального медицинского исследовательского центра детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 5 (2022); 544-552 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 5 (2022); 544-552 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: тест «Тромбодинамика», atrial fibrillation, direct oral anticoagulants, laboratory assays, bleeding, thrombodynamics test, фибрилляция предсердий, прямые оральные антикоагулянты, лабораторные методы, кровотечение

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2822/2360; https://www.rpcardio.com/jour/article/view/2822/2373; https://www.rpcardio.com/jour/article/downloadSuppFile/2822/767; https://www.rpcardio.com/jour/article/downloadSuppFile/2822/772; Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.; Петров В.И., Шаталова О.В., Герасименко А.С., и др. Безопасность применения прямых оральных антикоагулянтов у пациентов с фибрилляцией предсердий и хронической болезнью почек. Рациональная Фармакотерапия в Кардиологии. 2019;15(4):530-7. DOI:10.20996/1819-6446-2019-15-4-530-537.; Staerk L, Sherer JA, Ko D, et al. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ. Res. 2017;120(9):1501-17. DOI:10.1161/CIRCRESAHA.117.309732.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; Kimachi M, Furukawa TA, Kimachi K, et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst. Rev. 2017;11:CD011373. DOI:10.1002/14651858.CD011373.pub2.; Nazha B, Pandya B, Cohen J, et al. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Circulation. 2018;138:1402-1411. DOI:10.1161/CIRCULATIONAHA.117.031457.; Winter WE, Flax SD, Harris NS. Coagulation Testing in the Core Laboratory. Lab Med. 2017;48(4):295-313. DOI:10.1093/labmed/lmx050.; Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost. 2016;14(11):2194-201. DOI:10.1111/jth.13486.; Samuelson BT, Cuker A, Siegal DM, et al. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest. 2017;151(1):127-38. DOI:10.1016/j.chest.2016.08.1462.; Adcock DM, Gosselin RC. The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue. Int J Lab Hematol. 2017;39(suppl 1):37-40. DOI:10.1111/ijlh.12658.; Rodina TA, Mel’nikov ES, Aksenov AA, et al. Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum. Pharm Chem J. 2018;52(4): 372-7. DOI:10.1007/s11094-018-1824-3.; Rodina TA, Mel’nikov ES, Aksenov AA, et al. HPLC-MS/MS Method for Determining Dabigatran in Human Blood Serum. Pharmaceutical Chemistry Journal. 2018;51(12):1129-37. DOI:10.1007/s11094-018-1753-1.; Баландина А.Н., Кольцова Е.М., Атауллаханов Ф.И., и др. Тромбодинамика: новый подход к диагностике нарушений системы гемостаза. Вопросы Гематологии/Онкологии и Иммунопатологии в Педиатрии. 2018;17(4):114-26. DOI:10.24287/1726-1708-2018-17-4-114-126.; Joly BS, Sudrié-Arnaud B, Barbay V, et al. Thrombin generation test as a marker for high risk venous thrombosis pregnancies. J Thromb Thrombolysis. 2018;45(1):114-121. DOI:10.1007/s11239-017-1572-3.; Hunt H, Stanworth S, Curry N, et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst. Rev. 2015;2015(2):CD010438. DOI:10.1002/14651858.CD010438.pub2.; Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk. Lymphoma. 2015;56(12):3418-25. DOI:10.3109/10428194.2015.1041385.; Dias JD, Norem K, Doorneweerd DD, et al. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. Arch Pathol Lab Med. 2015;139(5):665-73. DOI:10.5858/arpa.2014-0170-OA.; Sinauridze EI, Vuimo TA, Tarandovskiy ID, et al. Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. Talanta. 2018;180:282-91. DOI:10.1016/j.talanta.2017.12.055.; Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 2011;127(3):S21-25. DOI:10.1016/S0049-3848(11)70007-X.; Balandina AN, Serebriyskiy II, Poletaev AV, et al. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PloS One. 2018;13(6):е0199900. DOI:10.1371/journal.pone.0199900.; Vuimo T, Belikov E, Litinskaya O. Efficiency of Thrombodynamics for Analysis of Hemostasis in Case of Transitory Ischemic Attack after Radio-frequency Ablation in a Patient with Paroxysmal Atrial Fibrillation. Am J Med Case Rep. 2015;3(10):333-7. DOI:10.12691/ajmcr-3-10-8.; Lipets EN, Ataullakhanov FI. Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb. J. 2015;13(1):4. DOI:10.1186/s12959-015-0038-0.; Calderara DB, Aliotta A, Zermatten MG, et al. Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters. Thromb Res. 2020;187:91-102. DOI:10.1016/j.thromres.2020.01.012.; Roullet S, Labrouche S, Freyburger G. Fibrinolysis during liver transplantation: analysis by the Thrombodynamics method. J Clin Pathol. 2019;72(9):636-8. DOI:10.1136/jclinpath-2018-205560.; Potze W, Adelmeijer J, Porte RJ, et al. Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis. Thromb Res. 2015;135(5):1012-16. DOI:10.1016/j.thromres.2015.02.025.; Soshitova NP, Karamzin SS, Balandina AN, et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics: Blood Coagul Fibrinolysis. 2012;23(6):498-507. DOI:10.1097/MBC.0b013e328352e90e.; Peshkova AD, Safiullina SI, Evtugina NG, et al. Premorbid Hemostasis in Women with a History of Pregnancy Loss. Thromb. Haemost. 2019;119(12):1994-2004. DOI:10.1055/s-0039-1696972.; Koltsova EM, Balandina AN, Grischuk KI, et al. The laboratory control of anticoagulant thromboprophylaxis during the early postpartum period after cesarean delivery. J Perinat Med. 2018;46(3):251-60. DOI:10.1515/jpm-2016-0333.; Fadeeva OA, Panteleev MA, Karamzin SS, et al. Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochem Biokhimiia. 2010;75(6):734-43. DOI:10.1134/s0006297910060088.; Сычев Д.А., Леванов А.Н., Цомая И.В. Клинико-фармакологическое и клиническое обоснование кратности применения новых пероральных антикоагулянтов. Кардиология. 2017;57(11):84-93. DOI:10087/cardio.2017.11.10058.; Крылов А.И., Шулутко А.М., Серебрицкий И.И. и др. Критерии эффективности антикоагулянтной терапии у пациентов с тромбозом глубоких вен нижних конечностей. Ангиология и Сосудистая Хирургия. 2015;21(1):36-43.; Крылов А.И., Шулутко А.М., Прасолов Н.В. и др. Коагулологические аспекты лечения осложнений пролонгированной терапии варфарином. Ангиология и Сосудистая Хирургия. 2016;22(3):33-41.; Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019;173:158-63. DOI:10.1016/j.thromres.2018.02.144.; Cove C, Albert CM, Andreotti F, et al. Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. Thromb Haemost. 2014;111(3):385-391. DOI:10.1160/TH13-04-0347.; Conway DSG, Heeringa J, Van Der Kuip DAM, et al. Atrial Fibrillation and the Prothrombotic State in the Elderly: The Rotterdam Study. Stroke. 2003;34(2):413-17. DOI:10.1161/01.str.0000051728.85133.32.; Ramanathan R, Gram JB, Sidelmann JJ, et al. Sex difference in fibrin clot lysability: Association with coronary plaque composition. Thromb Res. 2019;174:129-36. DOI:10.1016/j.thromres.2018.12.020.; Gram J, Skov J, Bladbjerg EM, et al. Gender Differences in Fibrin Polymerization and Lysability of Fibrin in Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2016;25(2):292-7. DOI:10.1016/j.jstrokecerebrovasdis.2015.09.031.; Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J Am Coll Cardiol. 1999;33(5):1424-6. DOI:10.1016/s0735-1097(99)00033-9.; Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001;103(13):1746-51. DOI:10.1161/01.cir.103.13.1746.; de Peuter OR, Kok WEM, Torp-Pedersen C, et al. Systolic heart failure: a prothrombotic state. Semin Thromb Hemost. 2009;35(5):497-504. DOI:10.1055/s-0029-1234145.; https://www.rpcardio.com/jour/article/view/2822

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2822
https://doi.org/10.20996/1819-6446-2022-09-07

Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation: Efficacy and Safety of Left Atrial Appendage Isolation and Oral Anticoagulants ; Профилактика кардиоэмболических осложнений у пациентов с фибрилляцией предсердий: сопоставление эффективности и безопасности эндоваскулярной изоляции ушка левого предсердия и оральных антикоагулянтов

Συγγραφείς: D. V. Pevzner, N. S. Kostritca, A. K. Alieva, I. A. Merkulova, I. S. Yavelov, E. V. Merkulov, I. E. Chazova, Д. В. Певзнер, Н. С. Кострица, А. К. Алиева, И. A. Меркулова, И. С. Явелов, Е. В. Меркулов, И. Е. Чазова

Συνεισφορές: The study was performed with the support of the National Medical Research Centre of Cardiology named after academician E.I. Chazov., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии имени академика Е.И. Чазова.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 4 (2022); 439-448 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 4 (2022); 439-448 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: кардиоэмболические осложнения, left atrial appendage occluder, direct oral anticoagulants, cardioembolic complications, окклюдер ушка левого предсердия, прямые оральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2795/2344; Virani, SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596. DOI:10.1161/cir.0000000000000757.; Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-88. DOI:10.1161/01.str.22.8.983.; Gabet A, Guenancia C, Duloquin G, Olie V, Bejot Y Ischemic Stroke With Atrial Fibrillation: Characteristics and Time Trends 2006 to 2017 in the Dijon Stroke Registry. Stroke. 2021;52(6):2077-85. DOI:10.1161/STROKEAHA.120.030812.; Odell JA, Blackshear JL, Davies E, et al. Thoracoscopic obliteration of the left atrial appendage: Potential for stroke reduction? Ann Thorac Surg. 1962;61(2):565-9. DOI:10.1016/0003-4975(95)00885-3.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; January ST, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-32. DOI:10.1016/j.jacc.2019.01.011.; Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiortiy trial. Lancet. 2009;374(9689):534-42. DOI:10.1016/S0140-6736(09)61343-X.; Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. DOI:10.1016/j.jacc.2014.04.029.; Osmancik P, Herman D, Neuzil P, et al. PRAGUE-17 Trial Investigators. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020;75(25):3122-35. DOI:10.1016/j.jacc.2020.04.067.; Glikson M, Wolff R, Hindricks G, et al. ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020;22(2):184. DOI:10.1093/europace/euz258.; Franco L, Becattini C, Beyer-Westendorf J, et al. Definition of major bleeding: Prognostic classification. J Thromb Haemost. 2020;18(11):2852-60. DOI:10.1111/jth.15048.; Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. J Am Med Assoc. 2014;312(19):1988-98. DOI:10.1001/jama.2014.15192.; Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.; Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. DOI:10.1016/S0140-6736(06)68845-4.; Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503. DOI:10.1016/S0140-6736(07)61233-1.; Reddy VY, Doshi SK, Kar S, et al. PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017;70(24):2964-75. DOI:10.1016/j.jacc.2017.10.021.; Давтян К.В., Калемберг А.А., Симонян Г.Ю. Эффективность профилактики ишемического инсульта у пациентов с имплантированным окклюзирующим устройством ушка левого предсердия. Результаты пятилетнего наблюдения. Российский Кардиологический Журнал. 2018;(7):16-20. DOI:10.15829/1560-4071-2018-7-16-20.; Turagam MK, Osmancik P, Neuzil P, et al. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol. 2020;76(23):2795-7. DOI:10.1016/j.jacc.2020.08.089.; Boersma LV, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37(31):2465-74. DOI:10.1093/eurheartj/ehv730.; Шугушев Э.Х., Родионова Л.В., Ганеева О.Н., и др. Непосредственные и отдаленные результаты имплантации окклюдера ушка левого предсердия у больных с фибрилляцией предсердия. Российский Кардиологический Журнал. 2020;(12):28-32. DOI:10.15829/1560-4071-2016-12-28-32.; Tzikas A, Shakir S, Gafoor S et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11(10):1170-9. DOI:10.4244/EIJY15M01_06.; https://www.rpcardio.com/jour/article/view/2795

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2795
https://doi.org/10.20996/1819-6446-2022-08-09

Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice ; Современная антикоагулянтная терапия при фибрилляции предсердий: приверженность пациентов в клинической практике

Συγγραφείς: Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin, Ю. П. Скирденко, Н. А. Николаев, К. Г. Переверзева, А. Ю. Тимакова, А. С. Галус, С. С. Якушин

Συνεισφορές: The study was performed with the support of the Omsk State Medical University., Исследование проведено при поддержке Омского государственного медицинского университета.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 1 (2022); 49-55 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 1 (2022); 49-55 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: приверженность, direct oral anticoagulants, atrial fibrillation, adherence, прямые оральные антикоагулянты, фибрилляция предсердий

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2674/2286; Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and beyond. Circ Res. 2020;127(1):21-33. DOI:10.1161/CIRCRESAHA.120.316575.; Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. 2020 Nov 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID:30252328 [cited 2021 Jun 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526072/.; Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217-21. DOI:10.1177/1747493019897870.; Kornej EJ, Benjamin EJ, Magnani JW. Atrial fibrillation: Global burdens and global opportunities. Heart. 2021;107(7):516-8. DOI:10.1136/heartjnl-2020-318480.; Storz MA, Helle P. Atrial fibrillation risk factor management with a plant-based diet: A review. J Arrhythm. 2019;35(6):781-8. DOI:10.1002/joa3.12254.; Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21stCentury: Novel Methods and New Insights. Circ Res. 2020;127(1):4-20. DOI:10.1161/CIRCRESAHA.120.316340.; Ардашев А.В., Беленков Ю.Н., Матюкевич М.Ч., Снежицкий В.А. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021;61(2):91-8. DOI:10.18087/CARDIO.2021.2.N1348.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 [цитировано 15.06.2021]. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf.; Кореннова О.Ю., Мальцев С.Н. Фибрилляция предсердий в реальной клинической практике: уроки одного регионального регистра. Трудный пациент. 2015;4(13):8-11.; Зверева П.И., Федорин М.М., Скирденко Ю.П., Николаев Н.А. Антитромботическая терапия при неклапанной фибрилляции предсердий: проблемы адекватного выбора. Медицинские Науки. 2018;(2):9-14.; Линчак Р.М., Компаниец О.Г., Недбайкин А.М., и др. Что думают и знают врачи об антитромботической терапии при фибрилляции предсердий? Кардиология. 2014;54(10):32-8. DOI:10.18565/cardio.2014.10.32-38.; Hurtado-Navarro I, García-Sempere A, Rodríguez-Bernal C, et al. Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain. Front Pharmacol. 2018;9:1353. DOI:10.3389/fphar.2018.01353.; Kim D, Yang PS, Jang E, et al. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Europace. 2020;22(4):547-57. DOI:10.1093/europace/euz273.; Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236. DOI:10.1186/s12872-01706716.; Николаев Н.А., Скирденко Ю.П. Российский универсальный опросник количественной оценки приверженности к лечению (КОП-25). Клиническая Фармакология и Терапия. 2018;27(1):74-8.; Скирденко Ю.П., Николаев Н.А. Оценка индивидуального риска пищевых взаимодействий на фоне приема варфарина. Терапевтический Архив. 2021;93(2):187-92. DOI:10.26442/00403660.2021.02.200611.; Баранова Е.И., Соболева А.В., Азнаурян Р.С., и др. Адекватность антитромботической терапии при неклапанной фибрилляции предсердий в реальной клинической практике. Атеротромбоз. 2015;(1):16-23.; Новикова Т.Н., Ашуров А.Б., Киселева М.В., и др. Профилактика инсульта у пациентов с фибрилляцией предсердий в клинической практике: эффективность и безопасность антикоагулянтной терапии. Кардиология. 2020;60(4):54-61. DOI:10.18087/cardio.2020.4.n1023.; Hernandez I, He M, Chen N, et al. Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. J Am Heart Assoc. 2019;8(12):27-9. DOI:10.1161/JAHA.118.011427.; Бунова С.С., Жернакова Н.И., Скирденко Ю.П., Николаев Н.А. Приверженность лекарственной терапии, модификации образа жизни и медицинскому сопровождению больных сердечно-сосудистыми заболеваниями. Кардиоваскулярная Терапия и Профилактика. 2020;19(6):38-42. DOI:10.15829/1728-8800-2020-2665.; Скирденко Ю.П., Николаев Н.А. Алгоритм выбора антикоагулянта для больных фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2020;16(2):199-205. DOI:10.20996/1819-6446-2020-04-1.; https://www.rpcardio.com/jour/article/view/2674

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2674
https://doi.org/10.20996/1819-6446-2022-02-03

Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 ; Применение антикоагулянтов после выписки больных COVID-19: что мы знаем к концу 2021 года

Συγγραφείς: I. Yavelov S., И. Явелов С.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); 908-915 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); 908-915 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: COVID-19, venous thromboembolism, deep vein thrombosis, pulmonary embolism, prevention, heparin, enoxaparin, direct oral anticoagulants, rivaroxaban, apixaban, betrixaban, новая коронавирусная инфекция, венозные тромбоэмболические осложнения, тромбоз глубоких вен, тромбоэмболия легочных артерий, профилактика, гепарин, эноксапарин, прямые оральные антикоагулянты, ривароксабан, апиксабан, бетриксабан

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2620/2251; Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19-associated coagulopathy and an-tithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524-e533. DOI:10.1016/S2352-3026(21)00105-8.; Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064-1070. DOI:10.1111/jth.15267.; Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342-6. DOI:10.1182/blood.2020007938.; Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism follow-ing hospital admission with COVID-19. Blood. 2020;136(11):1347-50. DOI:10.1182/blood.2020008086.; Bourguignon A, Beaulieu C, Belkaid W, et al. Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. Thromb Res. 2020;196:491-3. DOI:10.1016/j.thromres.2020.10.017.; Salisbury R, Iotchkova V, Jaafar S, et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Avd. 2020;4(24):6230-9. DOI:10.1182/bloodadvances.2020003349.; Roubinian NH, Dusendang JR, Mark DG, et al. Incidence of 30-Day Venous Thromboembo-lism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. JAMA Intern Med. 2021;181(7):997-1000. DOI:10.1001/jamainternmed.2021.0488.; Giannis D, Allen SL, Tsang J, et al., behalf of the Northwell COVID-19 Research Consorti-um. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838-47. DOI:10.1182/blood.2020010529.; Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis. 2006;22(1):31-8. DOI:10.1007/s11239-006-7732-5.; Hull RD, Schellong SM, Tapson VF, et al., EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8-18. DOI:10.7326/0003-4819-153-1-201007060-00004.; Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77. DOI:10.1056/NEJMoa1110899.; Cohen AT, Spiro TE, Büller HR, et al., MAGELLAN Investigators. Rivaroxaban for throm-boprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-23. DOI:10.1056/NEJ-Moa1111096.; Cohen AT, Harrington RA, Goldhaber SZ, et al., for the APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016;375(6):534-44. DOI:10.1056/NEJMoa1601747.; Spyropoulos AC, Ageno W, Albers GW, et al., for the MARINER Investigators. Rivaroxa-ban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018;379(12):1118-27. DOI:10.1056/NEJMoa1805090.; Spyropoulos AC, Ageno W, Albers GW, et al. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. JACC. 2020;75(25):3140-7. DOI:10.1016/j.jacc.2020.04.071.; XARELTO (rivaroxaban) tablets, for oral use. Highlights of prescribing information [cited 2021 Nov 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf.; Ribeiro MS, Dusilek C, Itinose K, et al., on behalf of the MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. 2021 Dec 15;S0140-6736(21)02392-8. doi:10.1016/S0140-6736(21)02392-8.; Ramacciotti E, Agati LB, Calderaro D, et al. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. Am Heart J. 2021;242:115-22. DOI:10.1016/j.ahj.2021.08.016.; https://www.rpcardio.com/jour/article/view/2620

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2620
https://doi.org/10.20996/1819-6446-2021-12-07

Anticoagulant therapy as a part of secondary stroke prevention in patients with atrial fibrillation ; Антикоагулянтная терапия в рамках вторичной профилактики инсульта у пациентов с фибрилляцией предсердий

Συγγραφείς: O. D. Ostroumova, T. M. Ostroumova, О. Д. Остроумова, Т. М. Остроумова

Συνεισφορές: Publication of this article has been supported by Pfizer., Статья опубликована при поддержке компании «Пфайзер».

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 3 (2022); 94-100 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 3 (2022); 94-100 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-3

Θεματικοί όροι: апиксабан, intracranial hemorrhage, secondary prevention, atrial fibrillation, direct oral anticoagulants, apixaban, внутричерепное кровоизлияние, вторичная профилактика, фибрилляция предсердий, прямые оральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1830/1422; GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0; Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 Jan;24(1):35-41. doi:10.1161/01.str.24.1.35; Министерство здравоохранения Российской Федерации. Рубрикатор клинических рекомендаций. Ишемический инсульт и транзиторная ишемическая атака у взрослых. ID: 171. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/171_2 (дата обращения 25.05.2022).; Hart RG, Catanese L, Perera KS, et al. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017 Apr;48(4):867-72. doi:10.1161/STROKEAHA.116.016414; Kolmos M, Christoffersen L, Kruuse C. Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2021 Aug;30(8):105935. doi:10.1016/j.jstrokecerebrovasdis.2021.105935; Gladstone DJ, Dorian P, Spring M, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke. 2015 Apr;46(4):936-41. doi:10.1161/STROKEAHA.115.008714; Thijs VN, Brachmann J, Morillo CA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology. 2016 Jan 19;86(3):261-9. doi:10.1212/WNL.0000000000002282; Zheng S, Yao B. Impact of risk factors for recurrence after the first ischemic stroke in adults: A systematic review and meta-analysis. J Clin Neurosci. 2019 Feb;60:24-30. doi:10.1016/j.jocn.2018.10.026; Аракелян МГ, Бокерия ЛА, Васильева ЕЮ и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594; Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke. 1983 Sep-Oct;14(5):688-93. doi:10.1161/01.str.14.5.688; Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007 Feb;38(2):423-30. doi:10.1161/01.STR.0000254600.92975.1f; Gabet A, Oli V, Bejot Y. Atrial Fibrillation in Spontaneous Intracerebral Hemorrhage, Dijon Stroke Registry (2006–2017). J Am Heart Assoc. 2021 Sep 7;10(17):e020040. doi:10.1161/JAHA.120.020040; DeSimone CV, Graff-Radford J, El-Harasis MA, et al. Cerebral Amyloid Angiopathy: Diagnosis, Clinical Implications, and Management Strategies in Atrial Fibrillation. J Am Coll Cardiol. 2017 Aug 29;70(9):1173-82. doi:10.1016/j.jacc.2017.07.724; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi:10.1093/eurheartj/ehaa612; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0; Umashankar K, Mammi M, Badawoud E, et al. Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: a Systematic Review and Meta-analysis. Cardiovasc Drugs Ther. 2022 Apr 25. doi:10.1007/s10557-022-07336-w. Online ahead of print.; Xian Y, Xu H, O’Brien EC, et al. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol. 2019 Oct 1;76(10):1192-202. doi:10.1001/jamaneurol.2019.2099; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi:10.1056/NEJMoa0905561. Epub 2009 Aug 30.; Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi:10.1056/NEJMoa1009638. Epub 2011 Aug 10.; Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi:10.1056/NEJMoa1107039. Epub 2011 Aug 27.; Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11. doi:10.1016/S1474-4422(12)70092-3. Epub 2012 May 8.; Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018 Dec;49(12):2933-44. doi:10.1161/STROKEAHA.118.020232; Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF Study. Stroke. 2015 Aug;46(8):2175-82. doi:10.1161/STROKEAHA.115.008891. Epub 2015 Jun 30.; Cappellari M, Carletti M, Danese A, Bovi P. Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2016 Oct;42(3):393-8. doi:10.1007/s11239-016-1393-9; Labovitz AJ, Rose DZ, Fradley MG, et al. Early Apixaban Use Following Stroke in Patients With Atrial Fibrillation: Results of the AREST Trial. Stroke. 2021 Apr;52(4):1164-71. doi:10.1161/STROKEAHA.120.030042. Epub 2021 Feb 25.; Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019 Jan;18(1):117-26. doi:10.1016/S1474-4422(18)30356-9; SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol. 2021 Oct;20(10):842-53. doi:10.1016/S1474-4422(21)00264-7; Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al; APACHE-AF Trial Investigators. Apixaban versus no anticoagulation after anticoagulationassociated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol. 2021 Nov;20(11):907-16. doi:10.1016/S1474-4422(21)00298-2; Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021 Jan;289(1):42-52. doi:10.1111/joim.13140. Epub 2020 Jul 16.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1830
https://doi.org/10.14412/2074-2711-2022-3-94-100

Cognitive impairment and small vessel disease in atrial fibrillation ; Когнитивные нарушения и болезнь мелких сосудов при фибрилляции предсердий

Συγγραφείς: P. M. Krupenin, O. N. Voskresenskaya, D. A. Napalkov, A. A. Sokolova, П. М. Крупенин, О. Н. Воскресенская, Д. А. Напалков, А. А. Соколова

Συνεισφορές: The investigation has been supported by the Russian Foundation for Basic Research under Scientific Project No. 19-015-00383., Исследование выполнено при финансовой поддержке РФФИ в рамках научного проекта № 19-015-00383.

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 6 (2022); 55-62 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 6 (2022); 55-62 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-6

Θεματικοί όροι: магнитно-резонансная томография, mild cognitive impairment, direct oral anticoagulants, cerebral small vessel disease, white matter hyperintensity, magnetic resonance imaging, умеренные когнитивные нарушения, прямые оральные антикоагулянты, церебральная болезнь мелких сосудов, гиперинтенсивность белого вещества

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1921/1477; Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-35. doi:10.1212/WNL.0000000000004826. Epub 2017 Dec 27.; Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-734. doi:10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20.; Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47. doi:10.1161/CIRCULATIONAHA.113.005119. Epub 2013 Dec 17.; Ter Telgte A, van Leijsen EMC, Wiegertjes K, et al. Cerebral small vessel disease: from a focal to a global perspective. Nat Rev Neurol. 2018;14(7):387-98. doi:10.1038/s41582-018-0014-y; Ihara M, Yamamoto Y. Emerging Evidence for Pathogenesis of Sporadic Cerebral Small Vessel Disease. Stroke. 2016 Feb;47(2):554-60. doi:10.1161/STROKEAHA.115.009627. Epub 2016 Jan 7.; Mustapha M, Nassir CMNCM, Aminuddin N, et al. Cerebral Small Vessel Disease (CSVD) – Lessons From the Animal Models. Front Physiol. 2019 Oct 24;10:1317. doi:10.3389/fphys.2019.01317; Gardarsdottir M, Sigurdsson S, Aspelund T, et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. Europace. 2018 Aug 1;20(8):1252-8. doi:10.1093/europace/eux220; La Montagne PJ, Benzinger TLS, Morris JC, et al. OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease. medRxiv. 2019 Jan 1;2019.12.13.19014902. doi:10.1101/2019.12.13.19014902; Tournier J-D, Smith R, Raffelt D, et al. MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation. Neuroimage. 2019 Nov 15;202:116137. doi:10.1016/j.neuroimage.2019.116137. Epub 2019 Aug 29.; Mayasi Y, Helenius J, McManus DD, et al. Atrial fibrillation is associated with anterior predominant white matter lesions in patients presenting with embolic stroke. J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):6-13. doi:10.1136/jnnp-2016-315457; Zhuang Y, Zeng X, Wang B, et al. Cortical surface thickness in the middle-aged brain with white matter hyperintense lesions. Front Aging Neurosci. 2017 Jul 17;9:225. doi:10.3389/fnagi.2017.00225; Stefansdottir H, Arnar DO, Aspelund T, et al. Atrial Fibrillation is Associated With Reduced Brain Volume and Cognitive Function Independent of Cerebral Infarcts. Stroke. 2013 Apr;44(4):1020-5. doi:10.1161/STROKEAHA.12.679381. Epub 2013 Feb 26.; Petrault M, Ouk T, Petrault O, et al. Safety of oral anticoagulants on experimental brain microbleeding and cognition. Neuropharmacology. 2019 Sep 1;155:162-72. doi:10.1016/j.neuropharm.2019.05.030. Epub 2019 May 24.; Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi:10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.; Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi:10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.; Grossmann K. Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease. Biomedicines. 2022 Aug 4;10(8):1890. doi:10.3390/biomedicines10081890; Chen N, Lutsey PL, MacLehose RF, et al. Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018 Nov 6;7(21):e009561. doi:10.1161/JAHA.118.009561; Kim D, Yang PS, Jang E, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace. 2021 Feb 5;23(2):184-95. doi:10.1093/europace/euaa192; Mitchell A, Snowball J, Welsh TJ, et al. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med. 2021 Aug 31;19(1):189. doi:10.1186/s12916-021-02067-5

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1921
https://doi.org/10.14412/2074-2711-2022-6-55-62

Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных

Συγγραφείς: О. В. Сомонова, Э. А. Антух, А. В. Варданян, Е. Г. Громова, Б. И. Долгушин, А. Л. Елизарова, Д. Д. Сакаева, В. Ю. Сельчук, А. А. Трякин, В. А. Черкасов

Πηγή: Malignant tumours; Том 12, № 3s2-2 (2022); 159-170 ; Злокачественные опухоли; Том 12, № 3s2-2 (2022); 159-170 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: прямые оральные антикоагулянты, тромбоэмболические осложнения, низкомолекулярные гепарины, гепарин натрия, фондапаринукс

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1071/767; https://www.malignanttumors.org/jour/article/view/1071

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1071
https://doi.org/10.18027/2224-5057-2022-12-3s2-159-170

Антикоагулянтная терапия при фибрилляции предсердий

Συγγραφείς: Тоиров Максуд Шарипович, Орзикулова Шахло Акмаловна

Πηγή: TA'LIM VA RIVOJLANISH TAHLILI ONLAYN ILMIY JURNALI; Vol. 2 No. 10 (2022): ТАЪЛИМ ВА РИВОЖЛАНИШ ТАҲЛИЛИ ОНЛАЙН ИЛМИЙ ЖУРНАЛИ; 225-233 ; 2181-2624

Θεματικοί όροι: антикоагулянты, варфарин, прямые оральные антикоагулянты, приверженность

Περιγραφή αρχείου: application/pdf

Relation: https://sciencebox.uz/index.php/ajed/article/view/4037/3625; https://sciencebox.uz/index.php/ajed/article/view/4037

Διαθεσιμότητα: https://sciencebox.uz/index.php/ajed/article/view/4037

Direct-acting oral anticoagulants in antiphospholipid syndrome ; Прямые оральные антикоагулянты при антифосфолипидном синдроме

Συγγραφείς: T. M. Reshetnyak, K. S. Nurbaeva, Т. М. Решетняк, К. С. Нурбаева

Πηγή: Rheumatology Science and Practice; Vol 58, No 6 (2020); 708-715 ; Научно-практическая ревматология; Vol 58, No 6 (2020); 708-715 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: антикоагулянты, direct-acting oral anticoagulants, antiphospholipid antibodies, thrombosis, anticoagulants, прямые оральные антикоагулянты, антифосфолипидные антитела, тромбоз

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2972/2046; Насонов ЕЛ. Антифосфолипидный синдром. М.: Изд-во «Литтера»; 2004:454.; Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. DOI:10.14412/1995-4484-2014-56-71; Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. DOI:10.1056/NEJMra1705454; Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. DOI:10.1111/j.1538-7836.2006.01753.x; Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. DOI:10.1111/j.1538-7836.2009.03674.x; Volkov I, Seguro L, Leon EP, et al. Profiles of criteria and noncriteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun Highlights. 2020;11(1):8. DOI:10.1186/s13317-020-00131-3; Tektonidou MG., Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI:10.1136/annrheumdis-2019-215213; Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151-2160. DOI:10.1182/blood-2017-09-805689; Taraborelli M, Reggia R, Dall’Ara F, et al. Long-term outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study. J Rheumatol. 2017;44(8):1165-1172. DOI:10.3899/jrheum.161364; Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. 2010;19(4):432-435. DOI:10.1177/0961203310361491; Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Blood. 2011;118(17):4714-4718. DOI:10.1182/blood-2011-03-340232; Asherson RA. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76-80. DOI:10.1016/j.autrev.2006.06.008; Jackson WG, Oromendia C, Unlu O, et al. Antiphospholipid syndrome alliance for clinical trials and international networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320-2324. DOI:10.1182/bloodadvances.2017008185; Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011-1018. DOI:10.1136/annrheumdis-2013-204838; Кондратьева ЛВ, Решетняк ТМ. Профилактика тромбозов при антифосфолипидном синдроме. Современная ревматология. 2009;3(3):18-22. DOI:10.14412/1996-7012-2009-552; Martinelli I, Abbattista M, Bucciarelli P, et al Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018;103(7):e315-e317. DOI:10.3324/haematol.2017.185132; Сатыбалдыева МА, Решетняк ТМ. Новые оральные антикоагулянты в терапии антифосфолипидного синдрома. Научно-практическая ревматология. 2016;54(2):219-226. doi:10.14412/1995-4484-2016-219-226; Hlavacek P, Guo JD, Rosenblatt L, et al. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin. 2019;35(12):2043-2051. DOI:10.1080/03007995.2019.1653067; Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. DOI:10.1161/JAHA.120.017559; Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S. DOI:10.1378/chest.11-2292; Almarshad F, Alaklabi A, Bakhsh E, Pathan A, Imegren M. Use of direct oral anticoagulants in daily practice. Am J Blood Res. 2018;8(4):57-72. DOI:10.1097/MBC.0000000000000247; Undas A, Goialczyk T. Direct oral anticoagulants in patients with thrombophilia: Challenges in diagnostic evaluation and treatment. Adv Clin Exp Med. 2016;25(6):1321-1330. DOI:10.17219/acem/65853; Cohen H, Hunt BJ, Efthymiou M, et al. RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426-e436. DOI:10.1016/S2352-3026(16)30079-5; Alberio L. The new direct oral anticoagulants in special indications. Rationale and preliminary data in cancer, mechanical heart valves, APS, HIT, and beyond. Semin Hematol. 2014;51(2):152-156. DOI:10.1053/j.seminhematol.2014.03.002; Arachchillage DR, Mackie IJ, Efthymiou M, et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost. 2016;14(11):2177-2186. DOI:10.1111/jth.13475; Balbi GGM, Pacheco MS, Monticielo OA, et al. Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Adv Rheumatol. 2020;60(1):29-43. DOI:10.1186/s42358-020-00125-9; Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: A focus on clinically relevant drug interactions. Blood. 2018;132(21):2230-2239. DOI:10.1182/blood-2018-06-848747; Ordi-Ros J, Saerz-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med. 2019;171(10):685-694. DOI:10.7326/M19-0291; Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015;26(4):476-477. DOI:10.1097/MBC.0000000000000247; Resseguier AS, Pereira B, Rieu V, et al. Direct oral anticoagulants: An alternative treatment for thrombotic antiphospholipid syndrome. Lupus. 2017;26(12):1297-1303. DOI:10.1177/0961203317701841; Betancur JF, Bonilla AF, Hormaza AA, et al. Direct oral anticoagulants in antiphospholipid syndrome: A real-life case series. Lupus. 2016;25(6):658-652. DOI:10.1177/0961203315624555; Hatadyj E, Olesinska M. Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia. 2016;54(3):146-149. DOI:10.5114/reum.2016.61217; Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14(8):680-685. DOI:10.1016/j.autrev.2015.03.007; Malec K, Goralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res. 2017;152:93-97. DOI:10.1016/j.thromres.2016.12.009; Kunk PR, Brown J, McShane M, et al. Direct oral anticoagulants in hypercoagulable states. J Thromb Thrombolysis. 2017;43(1):79-85. DOI:10.1007/s11239-016-1420-x; Signorelli F, Nogueira F, Domingues V, et al. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases. Clin Rheumatol. 2016;35(3):801-805. DOI:10.1007/s10067-015-3030-y; Schaefer JK, Mcbane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients. Thromb Haemost. 2014;112(5):947-950. DOI:10.1160/TH14-03-0272; Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014;89(10):1017. DOI:10.1002/ajh.23797; Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patient with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. DOI:10.1182/blood-2018-04-848333; Cortes-Hernandez J, S;iez Comet L, Perez-Conesa M, et al. Rivaroxaban versus warfarin as secondary thromboprophylaxis in patients with antiphospholipid syndrome protocol: a randomized, multicenter, open-label, clinical trial. Ann Intern Med. 2019;171(10):685-694. DOI:10.7326/M19-0291; Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabiga-tran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. DOI:10.1056/NEJMoa1113697; Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. DOI:10.1161/CIRCULATIONAHA.113.004450; Woller SC, Stevens SM, Kaplan DA, Rondina MT. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study (Letter to editor). Clin Appl Thromb Hemost. 2016;22(3):239-247. DOI:10.1177/1076029615615960; ISRCTN10280992. Rivaroxaban for stroke patients with antiphospholipid syndrome. DOI:10.1186/ISRCTN10280992; Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. DOI:10.1016/j.autrev.2018.04.0; Sanchez-Redondo J, Espinosa G, Varillas DD, Cervera R. Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: A systematic literature review and meta-analy-sis. Clin Ther. 2019;41(9):1839-1862. DOI:10.1016/j.clin-thera.2019.06.015; Elsebaie MAT, van Es N, Langston A, Buller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and met analysis. J Thromb. Haemost. 2019;17(4):645-656. DOI:10.1111/jth.14398; Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. Autoimmun Rev. 2020;Nov 13:102711. DOI:10.1016/j.autrev.2020.102711; Cerda P, Becattini C, Iriarte A, et al. Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis. Eur J Intern Med. 2020;79:43-50. DOI:10.1016/j.ejim.2020.05.012; Satybaldyeva MA, Seredavkina NV, Nasonov EL, Lila AM, Reshetnyak TM. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. URL: https://academy.isth.org/isth/2019/melbourne/264291/nataliya.seredavkina.dabigatran.for.failed.warfarin.treatment.in.high-risk.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D-Dabigatran+for+failed+warfarin+treatment+in+high-risk+patients+with+antiphospholipid+syndrome (Date accessed: 2020).; Bala MM, Celinska-Lowenho M, Szot W, Padjas A, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2020;10:CD012169. DOI:10.1002/14651858.CD012169.pub3; European Medicines Agency (EMA). PRAC recommendations on signals. 2019 May 6; URL: https://www.ema.europa.eu/en/docu-ments/prac-recommendation/prac-recommendations-signals-ad-opted-8-11-april-2019-prac-meeting_en.pdf (Date accessed: 2020).; Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): Increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome. URL: https://www.gov.uk/drug-safety-update/direct-act-ing-oral-anticoagulants-doacs-increased-risk-of-recurrent-throm-botic-events-in-patients-with-antiphospholipid-syndrome (Date accessed: 2020).; Arachchillage DRJ, Gomez K, Alikhan R, et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): Use of direct acting oral anticoagulants. Br J Haematol. 2020;189(2):212-215. DOI:10.1111/bjh.16308.; Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. DOI:10.1093/eurheartj/ehz405; Agence Nationale de Securite du Medicaments (ANSM). Anticoagulants Oraux Directs (AODs) (apixaban (Eliquis®), rivaroxaban (Xarelto®), dabigatran (Pradaxa®) et edoxaban (Lixiana®/ Roteas®) non recommandes chez les patients presentant un Syndrome des Antiphospholipides (SAPL) - Lettre aux profession-nels de sante. 2019 May 24. URL: https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Anticoagulants-Oraux-Directs-AODs-apixaban-Eliquis-R-rivaroxaban-Xarelto-R-dabigatran-Pradaxa-R-et-edoxaban-Lix-iana-R-Roteas-R-non-recommandes-chez-les-patients-presentant-un-Syndrome-des-Antiphospholipides-SAPL-Lettre-aux-profes-sionnels-de-sante (Date accessed: 2020).; Bauersachs R, Langer F, Kalka C, et al. Treatment of the antiphospholipid syndrome with direct oral anticoagulants: Position statement of German societies. Vasa. 2019;48(6):483-486. DOI:10.1024/0301-1526/a000815; Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(9):2126-2137. DOI:10.1111/jth.1

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2972
https://doi.org/10.47360/1995-4484-2020-708-715

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage ; Антикоагулянтная терапия при фибрилляции предсердий у пациентов с внутричерепным кровоизлиянием

Συγγραφείς: A. Gerasimenko S., V. Gorbatenko S., O. Shatalova V., V. Petrov I., А. Герасименко С., В. Горбатенко С., О. Шаталова В., В. Петров И.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 303-309 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 303-309 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: atrial fibrillation, intracranial hemorrhage, hemorrhagic stroke, direct oral anticoagulants, warfarin, фибрилляция предсердий, внутричерепное кровоизлияние, геморрагический инсульт, прямые оральные антикоагулянты, варфарин

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2441/2153; Kirch- hof P, Benussi S, Kotecha D, и др. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский Кардиологический Журнал. 2017;(7):7-86. DOI:10.15829/1560-4071-2017-7-7-86.; Zhou Z, Yu J, Carcel C, et al. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open. 2018;8(5):e019672. DOI:10.1136/bmjopen-2017-019672.; Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8(4):355-69. DOI:10.1016/S1474-4422 (09)70025-0.; D'Amore C, Paciaroni M, Silvestrelli G, et al. Severity of acute intracerebral haemorrhage, elderly age and atrial fibrillation: independent predictors of poor outcome at three months. Eur J Intern Med. 2013;24(4):310-13. DOI:10.1016/j.ejim.2012.12.007.; Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010;30(5):565- 72. DOI:10.1055/s-0030-1268866.; Christensen H, Cordonnier C, Korv J, et al. European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage. Eur Stroke J. 2019;4(4):294-306. DOI:10.1177/2396987319849763.; Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015;78:54-62. DOI:10.1002/ana.24416.; Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in pa-tients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566-73. DOI:10.1016/S1474-4422(16)00110-1.; Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385:2077-87. DOI:10.1016/S0140-6736(14)61685-8.; Sarode R, Milling TJ Jr., Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma- controlled, phase IIIb study. Circulation. 2013;128:1234-43. DOI:10.1161/CIRCULATIONAHA.113.002283.; Галстян Г.М. Применение концентратов протромбинового комплекса по утвержденным и неутвержденным показаниям: новые перспективы старых препаратов. Гематология и Трансфу-зиология. 2018;63(1):78-91]. DOI:10.25837/HAT.2018.30.1.008.; Imberti D, Barillari G, Biasioli C, et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus. 2011;9:148-55. DOI:10.2450/2011.0065-10.; Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to war-farin overdose. Transfusion. 2009;49:1171-7. DOI:10.1111/j.1537-2995.2008.02080.x.; Yasaka M, Sakata T, Minematsu K, et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002;108:25- 30. DOI:10.1016/s0049-3848(02)00402-4.; Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77:477-80. PMID: 9065997.; Patriquin C, Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol. 2011;4(6):657-65. DOI:10.1586/ehm.11.59.; Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-37. DOI:10.1056/NEJMoa0707534.; Шахматова О.О. Специфический антаго-нист дабигатрана идаруцизумаб: что известно на сегодняшний день. Атеротромбоз. 2018;(2):147-57. DOI:10.21518/2307-1109-2018-2-147-158.; Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431-41. DOI:10.1056/NEJMoa1707278.; Young-A H. Andexanet Alfa: First Global Approval. Drugs. 2018;78(10):1049-55. DOI:10.1007/s40265-018-0940-4.; Ревишвили А.Ш., Шляхто Е.В., Замятин М.Н. и др. Особенности оказания экстренной и неотложной медицинской помощи пациентам, получающим прямые оральные антикоагулянты. Согласительный документ междисциплинарной группы экспертов. Вестник Аритмологии. 2018;(92):59-72. DOI:10.25760/VA-2018-92-59-72.; Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;4;380(14):1326-1335. DOI:10.1056/NE-JMoa1814051.; Diener HC, Stanford S, Abdul-Rahim A, et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Rev Neurother. 2014;14:1019-28. DOI:10.1586/14737175.2014.945435.; Sadighia А, Waskoa L, DiCristina H, et al. Long-term outcome of resuming anticoagulation after an-ticoagulation-associated intracerebral hemorrhage. eNeurologicalSci. 2020;18:100222. DOI:10.1016/j.ensci.2020.100222.; Murthy SB, Gupta A, Merkler AE, et al. Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Stroke. 2017;48(6):1594-600. DOI:10.1161/STROKEAHA.116.016327.; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.; Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NEJMoa1107039.; Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. DOI:10.1056/NEJMoa1009638.; Van Nieuwenhuizen KM, van der Worp HB, Algra A, et al. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials. 2015;4(16):393. DOI:10.1186/s13063-015-0898-4.; AlKherayf F, Xu Y, Gandara E, et al. Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. Thromb Res. 2016;144:152-7. DOI:10.1016/j.thromres.2016.06.014.; Диагностика и лечение фиб-рилляции предсердий. Клинические Рекомендации (2017). Доступно на: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf.; Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Asso- ciation/American Stroke Association. Stroke. 2015;46(7):2032-60. DOI:10.1161/STR.0000000000000069.; https://www.rpcardio.com/jour/article/view/2441

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2441
https://doi.org/10.20996/1819-6446-2021-04-13

Difficult issues in the management of patients with atrial fibrillation: a neurologist's point of view ; Сложные вопросы ведения пациента с фибрилляцией предсердий с точки зрения невролога

Συγγραφείς: A. A. Kulesh, А. А. Кулеш

Συνεισφορές: Publication of this article has been supported by Pfizer., Статья опубликована при поддержке компании «Пфайзер».

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 5 (2021); 4-13 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 5 (2021); 4-13 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-5

Θεματικοί όροι: прямые оральные антикоагулянты, atrial fibrillation, prevention, direct oral anticoagulants, фибрилляция предсердий, профилактика

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1659/1302; https://nnp.ima-press.net/nnp/article/view/1659/1328; Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019 Jan;18(1):117-26. doi:10.1016/S1474-4422(18)30356-9; Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke. 1983 Sep-Oct;14(5):688-93. doi:10.1161/01.str.14.5.688; Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke. 2015 Aug;46(8):2175-82. doi:10.1161/STROKEAHA.115.008891; Paciaroni M, Agnelli G, Falocci N, et al. Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. J Neurol. 2016 Feb;263(2):231-7. doi:10.1007/s00415-015-7957-3; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375; Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2017 Aug;12(6):589-96. doi:10.1177/1747493017700663. Epub 2017 Mar 15.; Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi:10.1093/eurheartj/ehaa612; Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019 Sep;4(3):198-223. doi:10.1177/2396987319841187; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0; Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi:10.1056/NEJMoa1107039; Парфенов ВA, Вербицкая СB. Вторичная профилактика инсульта при фибрилляции предсердий, применение апиксабана (исследования ARISTOTLE, AVERROES). Неврология, нейропсихиатрия, психосоматика. 2014;6(2S):7-14. doi:10.14412/2074-2711-2014-2S-7-14; Rutherford OW, Jonasson C, Ghanima W, et al. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):75-85. doi:10.1093/ehjcvp/pvz086; Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017 Aug;48(8):2142-9. doi:10.1161/STROKEAHA.117.017474; Diener HC, Hankey GJ, Easton JD, et al. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl. 2020 Sep 15;22(Suppl I):I13-I21. doi:10.1093/eur-heartj/suaa104; Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi:10.1161/STROKEAHA.117.018395; Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609-78. doi:10.1093/europace/euw295; Eun MY, Kim JY, Hwang YH, et al. Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke. J Stroke. 2021 Jan;23(1):113-23. doi:10.5853/jos.2020.03440; Warner JJ, Harrington RA, Sacco RL, Elkind MSV. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019 Dec;50(12):3331-2. doi:10.1161/STROKEAHA.119.027708; Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Apr 25:euab065. doi:10.1093/europace/euab065; Seiffge DJ, Traenka C, Polymeris A, et al. Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology. 2016 Nov 1;87(18):1856-62. doi:10.1212/WNL.0000000000003283; Arihiro S, Todo K, Koga M, et al; SAMURAI Study Investigators. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI – Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke. 2016 Jul;11(5):565-74. doi:10.1177/1747493016632239; Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc. 2017 Nov 29;6(12):e007034. doi:10.1161/JAHA.117.007034; Wilson D, Ambler G, Banerjee G, et al; Clinical relevance of Microbleeds in Stroke (CROMIS-2) collaborators. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):320-5. doi:10.1136/jnnp-2018-318890; Yaghi S, Trivedi T, Henninger N, et al. Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk. Ann Neurol. 2020 Oct;88(4):807-16. doi:10.1002/ana.25844; Abdul-Rahim AH, Fulton RL, Frank B, et al; VISTA collaborators. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol. 2015 Jul;22(7):1048-55. doi:10.1111/ene.12577; Yoshimura S, Uchida K, Sakai N, et al. Safety of Early Administration of Apixaban on Clinical Outcomes in Patients with Acute Large Vessel Occlusion. Transl Stroke Res. 2021 Apr;12(2):266-74. doi:10.1007/s12975-020-00839-4; Alrohimi A, Buck B, Jickling G, et al. Early apixaban therapy after ischemic stroke in patients with atrial fibrillation. J Neurol. 2021 May;268(5):1837-46. doi:10.1007/s00415-020-10335-2; Hong KS, Kwon SU, Lee SH, et al; Phase 2 Exploratory Clinical Study to Assess the Effects of Xarelto (Rivaroxaban) Versus Warfarin on Ischemia, Bleeding, and Hospital Stay in Acute Cerebral Infarction Patients With Non-valvular Atrial Fibrillation (Triple AXEL) Study Group. Rivaroxaban vs Warfarin Sodium in the UltraEarly Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2017 Oct 1;74(10):1206-15. doi:10.1001/jamaneurol.2017.2161; Butcher KS, Ng K, Sheridan P, et al. Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke. Stroke. 2020 Apr;51(4):1190-8. doi:10.1161/STROKEAHA.119.027569; Labovitz AJ, Rose DZ, Fradley MG, et al; AREST Investigators. Early Apixaban Use Following Stroke in Patients with Atrial Fibrillation: Results of the AREST Trial. Stroke. 2021 Apr;52(4):1164-71. doi:10.1161/STROKEAHA.120.030042; Mac Grory B, Flood S, Schrag M, et al. Anticoagulation Resumption After Stroke from Atrial Fibrillation. Curr Atheroscler Rep. 2019 May 20;21(8):29. doi:10.1007/s11883-019-0790-x; Vannucchi V, Moroni F, Grifoni E, et al. Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. J Thromb Thrombolysis. 2020 Jan;49(1):86-93. doi:10.1007/s11239-019-01972-0; Giustozzi M, Acciarresi M, Agnelli G, et al. Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke. 2020 Aug;51(8):2347-54. doi:10.1161/STROKEAHA.120.030143; Yaghi S, Willey JZ, Cucchiara B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Dec;48(12):e343-e361. doi:10.1161/STR.0000000000000152; Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke. 1999 Jul;30(7):1326-32. doi:10.1161/01.str.30.7.1326; Jensen M, Schlemm E, Cheng B, et al. Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial. Front Neurol. 2020 Aug 28;11:957. doi:10.3389/fneur.2020.00957; Muscari A, Faccioli L, Lega MV, et al. Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes. Brain Behav. 2020 Jan;10(1):e01497. doi:10.1002/brb3.1497; Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008 Aug;39(8):2249-56. doi:10.1161/STROKEAHA.107.510321; Paciaroni M, Bandini F, Agnelli G, et al. Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. J Am Heart Assoc. 2018 Nov 20;7(22):e010133. doi:10.1161/JAHA.118.010133; Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020 Jan;106(2):119-26. doi:10.1136/heartjnl-2019-315307; Ozaki AF, Choi AS, Le QT, et al. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and MetaAnalysis. Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969; Mainbourg S, Cucherat M, Provencher S, et al; META-EMBOL group. Twice- or OnceDaily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Thromb Res. 2021 Jan;197:24-32. doi:10.1016/j.thromres.2020.10.011; Meya L, Polymeris AA, Schaedelin S, et al. Oral Anticoagulants in Atrial Fibrillation Patients With Recent Stroke Who Are Dependent on the Daily Help of Others. Stroke. 2021 Jul 27:STROKEAHA120033862. doi:10.1161/STROKEAHA.120.033862; Chen LY, Leening MJ, Norby FL, et al. Carotid Intima-Media Thickness and Arterial Stiffness and the Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. J Am Heart Assoc. 2016 May 20;5(5):e002907. doi:10.1161/JAHA.115.002907; Wang Z, Korantzopoulos P, Liu T. Carotid Atherosclerosis in Patients with Atrial Fibrillation. Curr Atheroscler Rep. 2019 Nov 29;21(12):55. doi:10.1007/s11883-019-0808-4. Erratum in: Curr Atheroscler Rep. 2019 Dec 10;22(1):1.; Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic Stroke in Patients with Atrial Fibrillation. Angiology. 2019 Apr;70(4):299-304. doi:10.1177/0003319718791711; Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Jul 19:ehab390. doi:10.1093/eurheartj/ehab390; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная болезнь мелких сосудов: классификация, клинические проявления, диагностика и особенности лечения. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):4-17. doi:10.14412/2074-2711-2019-3S-4-17; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная спорадическая неамилоидная микроангиопатия: патогенез, диагностика и особенности лечебной тактики. Неврология, нейропсихиатрия, психосоматика. 2018;10(4):13-22. doi:10.14412/2074-2711-2018-4-13-22; Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-96. doi:10.1016/S1474-4422(19)30079-1; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Геморрагические проявления церебральной амилоидной ангиопатии – от патогенеза к клиническому значению. Неврология, нейропсихиатрия, психосоматика. 2018;10(3):4-11.; Данченко ИЮ, Кулеш АА, Дробаха ВЕ и др. Синдром CADASIL: дифференциальная диагностика с рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10-2):128-36. doi:10.17116/jnevro201911910128; Кулеш АА, Сыромятникова ЛИ. Терапия оральными антикоагулянтами у пациентов после внутримозгового кровоизлияния. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):4-10. doi:10.14412/2074-2711-2020-3-4-10; Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration: a united approach. Lancet Neurol. 2013;12:822-38. doi:10.1016/S1474-4422(13)70124-8; Petrault M, Casolla B, Ouk T, et al. Cerebral microbleeds: Beyond the macroscope. Int J Stroke. 2019 Jul;14(5):468-75. doi:10.1177/1747493019830594. Epub 2019 Feb 12.; Graff-Radford J, Lesnick T, Rabinstein AA, et al. Cerebral microbleed incidence, relationship to amyloid burden: The Mayo Clinic Study of Aging. Neurology. 2020 Jan 14;94(2):e190-e199. doi:10.1212/WNL.0000000000008735; Wilson D, Ambler G, Shakeshaft C, et al; CROMIS-2 Collaborators. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol. 2018;17:539-47. doi:10.1016/S1474-4422(18)30145-5; Marti-Fabregas J, Medrano-Martorell S, Merino E, et al; HERO Study Investigators. MRI predicts intracranial hemorrhage in patients who receive longterm oral anticoagulation. Neurology. 2019;92:e2432-e2443. doi:10.1212/WNL.0000000000007532; Wilson D, Ambler G, Lee KJ, et al; Microbleeds International Collaborative Network. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2019 Jul;18(7):653-65. doi:10.1016/S14744422(19)30197-8; Casolla B, Cordonnier C. Intracerebral haemorrhage, microbleeds and antithrombotic drugs. Rev Neurol (Paris). 2021 Jan-Feb;177(1-2):11-22. doi:10.1016/j.neurol.2020.05.008; Best JG, Ambler G, Wilson D, et al; Microbleeds International Collaborative Network. Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2021 Apr;20(4):294-303. doi:10.1016/S1474-4422(21)00024-7; Tsai CT, Liao JN, Chiang CE, et al. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. JAMA Netw Open. 2020 Jun 1;3(6):e206424. doi:10.1001/jamanetworkopen.2020.6424; Guo Z, Ding X, Ye Z, et al. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies. Clin Cardiol. 2021 Jul;44(7):917-24. doi:10.1002/clc.23647; Ntaios G. Embolic Stroke of Undetermined Source: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 Jan 28;75(3):333-40. doi:10.1016/j.jacc.2019.11.024; Tsivgoulis G, Katsanos AH, Köhrmann M, et al. Duration of Implantable Cardiac Monitoring and Detection of Atrial Fibrillation in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis. J Stroke. 2019 Sep;21(3):302-11. doi:10.5853/jos.2019.01067; Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013 Dec;44(12):3357-64. doi:10.1161/STROKEAHA.113.001884; Rubio Campal JM, Garcia Torres MA, Sanchez Borque P, et al. Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (from the DAF-ESUS registry). Am J Cardiol. 2020 Feb 1;125(3):409-14. doi:10.1016/j.amjcard.2019.10.050; Kitsiou A, Rogalewski A, Kalyani M, et al. Atrial Fibrillation in Patients with Embolic Stroke of Undetermined Source during 3 Years of Prolonged Monitoring with an Implantable Loop Recorder. Thromb Haemost. 2021 Jun;121(6):826-33. doi:10.1055/a-1346-2899; Elkind MSV. Atrial Cardiopathy and Stroke Prevention. Curr Cardiol Rep. 2018 Sep 12;20(11):103. doi:10.1007/s11886-018-1053-0; Schnabel RB, Haeusler KG, Healey JS, et al. Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. Circulation. 2019 Nov 26;140(22):1834-50. doi:10.1161/CIRCULATIONAHA.119.040267; Poli S, Diedler J, Härtig F, et al. Insertable cardiac monitors after cryptogenic stroke a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol. 2016 Feb;23(2):375-81. doi:10.1111/ene.12843; Markus A, Valerie S, Mira K. Promising Biomarker Candidates for Cardioembolic Stroke Etiology. A Brief Narrative Review and Current Opinion. Front Neurol. 2021 Feb 25;12:624930. doi:10.3389/fneur.2021.624930; Wasser K, Weber-Krüger M, Gröschel S, et al. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AFRANDOMISED Trial. Stroke. 2020 Feb;51(2):395-401. doi:10.1161/STROKEAHA.119.026496; Zhang K, Kamtchum-Tatuene J, Li M, Jickling GC. Cardiac natriuretic peptides for diagnosis of covert atrial fibrillation after acute ischaemic stroke: a meta-analysis of diagnostic accuracy studies. Stroke Vasc Neurol. 2021 Mar;6(1):128-32. doi:10.1136/svn-2020-000440; Мехряков СА, Кулеш АА, Сыромятникова ЛИ, Собянин КВ. Биомаркеры предсердной кардиопатии у пациентов с разными патогенетическими подтипами ишемического инсульта. Неврология, нейропсихиатрия, психосоматика. 2020;12(6):33-41. doi:10.14412/2074-2711-2020-6-33-41; Patel K, Mikhael E, Liu M, et al. Anticoagulation Therapy Reduces Recurrent Stroke in Embolic Stroke of Undetermined Source Patients With Elevated Coagulation Markers or Severe Left Atrial Enlargement. Front Neurol. 2021 Jun 7;12:695378. doi:10.3389/fneur.2021.695378; Kamel H, Longstreth WT Jr, Tirschwell DL, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019 Feb;14(2):207-14. doi:10.1177/1747493018799981

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1659
https://doi.org/10.14412/2074-2711-2021-5-4-13

Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results ; Влияние полиморфизмов генов CYP3A4*22 (rs35599367) C > T, CYP3A5*3 (rs776746) A > G, ABCB1 (rs4148738) C > T и ABCB1 (rs1045642) C > T на антикоагулянтное действие апиксабана: результаты пилотного исследования

Συγγραφείς: I. N. Sychev, L. V. Fedina, A. S. Osipov, I. I. Temirbulatov, O. Yu. Tataroy, Zh. A. Sozaeva, K. A. Akmalova, N. P. Denisenko, S. P. Abdullaev, A. A. Kachanova, E. A. Grishina, K. B. Mirzaev, D. A. Sychev, И. Н. Сычев, Л. В. Федина, А. С. Осипов, И. И. Темирбулатов, О. Ю. Татарой, Ж. А. Созаева, К. А. Акмалова, Н. П. Денисенко, Ш. П. Абдуллаев, А. А. Качанова, Е. А. Гришина, К. Б. Мирзаев, Д. А. Сычев

Πηγή: Meditsinskiy sovet = Medical Council; № 4 (2021); 41-46 ; Медицинский Совет; № 4 (2021); 41-46 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: CYP3A5, direct oral anticoagulants, pharmacogenetics, personalized medicine, ABCB1, CYP3A4, прямые оральные антикоагулянты, фармакогенетика, персонализированная медицина

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6089/5549; Seeger J., Wöhrle J. Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation. Core Evid. 2020;15:1–6. doi:10.2147/CE.S172935.; Byon W., Garonzik S., Boyd R.A., Frost C.E. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–1279. doi:10.1007/s40262-019-00775-z.; Granger C.B., Alexander J.H., McMurray J.J. V., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039.; Loo S.Y., Dell’Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–2106. doi:10.1111/bcp.13299.; Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393.; Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–88. doi:10.1093/ejcts/ezw313.; Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., Annest J.L. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–1866. doi:10.1001/jama.296.15.1858.; Tepper P.G., Mardekian J., Masseria C., Phatak H., Kamble S., Abdulsattar Y. et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One. 2018;13(11):e0205989. doi:10.1371/journal.pone.0205989.; Adeboyeje G., Sylwestrzak G., Barron J.J., White J., Rosenberg A., Abarca J. et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):968–978. doi:10.18553/jmcp.2017.23.9.968.; Garcia D.A., Fisher D.A., Mulder H., Wruck L., De Caterina R., Halvorsen S. et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020;221:1–8. doi:10.1016/j.ahj.2019.10.013.; Brighton T. Experimental and clinical pharmacology: New oral anticoagulant drugs – mechanisms of action. Aust Prescr. 2010;33:38–41. doi:10.18773/austprescr.2010.017.; Kubisz P., Stanciakova L., Dobrotova M., Samos M., Mokan M., Stasko J. Apixaban – Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):609–621. doi:10.2174/1389200218666170424151551.; Ašić A., Marjanović D., Mirat J., Primorac D. Pharmacogenetics of novel oral anticoagulants: A review of identified gene variants & future perspectives. Per Med. 2018;15(3):209–221. doi:10.2217/pme-2017-0092.; Hanigan S., Das J., Pogue K., Barnes G.D., Dorsch M.P. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636–643. doi:10.1007/s11239-020-02037–3.; Сычев Д.А., Сычев И.Н., Мирзаев К. Б, Рыткин Э.И., Иващенко Д.В., Буре И.В. Клинико-фармакологические технологии персонализации фармакотерапии сердечно-сосудистых заболеваний: фокус на прямые оральные антикоагулянты. Вестник российской академии медицинских наук. 2019;74(5):299–306. doi:10.15690/vramn1214.; Sweezy T., Mousa S.A. Genotype-guided use of oral antithrombotic therapy: A pharmacoeconomic perspective. Vol. 11. Per Med. 2014;11(2): 223–235. doi:10.2217/pme.13.106.; Raymond J., Imbert L., Cousin T., Duflot T., Varin R., Wils J., Lamoureux F. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021;11(1):37. doi:10.3390/jpm11010037.; Dimatteo C., D’Andrea G., Vecchione G., Paoletti O., Tiscia G.L., Santacroce R. et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016;145:24–26. doi:10.1016/j.thromres.2016.07.005.; Kryukov A.V., Sychev D.A., Andreev D.A., Ryzhikova K.A., Grishina E.A., Ryabova A.V. et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018;11:43–49. doi:10.2147/PGPM.S157111.; Ueshima S., Hira D., Kimura Y., Fujii R., Tomitsuka C., Yamane T. et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018;84(6):1301–1312. doi:10.1111/bcp.13561.; Huppertz A., Grond-Ginsbach C., Dumschat C., Foerster K.I., Burhenne J., Weiss J. et al. Unexpected excessive apixaban exposure: Case report of a patient with polymorphisms of multiple apixaban elimination pathways. BMC Pharmacol Toxicol. 2019;20(1):53. doi:10.1186/s40360-019-0331-9.; Gulilat M., Keller D., Linton B., Pananos A.D., Lizotte D., Dresser G.K. et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombolysis. 2020;49(2):294–303. doi:10.1007/s11239-019-01962-2.; Conway S.E., Hwang A.Y., Ponte C.D., Gums J.G. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. Vol. 37. Pharmacotherapy. 2017;37(2):236–248. doi:10.1002/phar.1884.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/6089
https://doi.org/10.21518/2079-701X-2021-4-41-46

Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных

Συγγραφείς: О. В. Сомонова, Э. А. Антух, А. В. Варданян, Е. Г. Громова, Б. И. Долгушин, А. Л. Елизарова, Д. Д. Сакаева, В. Ю. Сельчук, А. А. Трякин, В. А. Черкасов

Πηγή: Malignant tumours; Том 11, № 3s2-2 (2021); 145-155 ; Злокачественные опухоли; Том 11, № 3s2-2 (2021); 145-155 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: прямые оральные антикоагулянты, тромбоэмболические осложнения, низкомолекулярные гепарины, гепарин натрия, фондапаринукс

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/900/648; https://www.malignanttumors.org/jour/article/view/900

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/900
https://doi.org/10.18027/2224-5057-2021-11-3s2-47

The Effect of Various Types of Anticoagulant Therapy on the Reduction of Mortality in COVID-19 ; Влияние различных видов антикоагулянтной терапии на снижение летальности при COVID-19

Συγγραφείς: Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tretyakova M.V., Shkoda A.S., Elalamy I., Di Renzo G., Rizzo G., Pyatigorskaya N.V., Solopova A.G., Grigoreva K.N., Nakaidze I.A., Mitryuk D.V.

Συνεισφορές: 1

Πηγή: Annals of the Russian academy of medical sciences; Vol 76, No 3 (2021); 268-278 ; Вестник Российской академии медицинских наук; Vol 76, No 3 (2021); 268-278 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.763

Θεματικοί όροι: anticoagulants, COVID-19, thrombosis, low-molecular-weight heparin, direct-acting oral anticoagulants, антикоагулянты, тромбозы, низкомолекулярные гепарины, прямые оральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://vestnikramn.spr-journal.ru/jour/article/view/1551/1458; https://vestnikramn.spr-journal.ru/jour/article/view/1551/1471; https://vestnikramn.spr-journal.ru/jour/article/view/1551/1478; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/1551/1974; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/1551/2035; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/1551/2036

Διαθεσιμότητα: https://vestnikramn.spr-journal.ru/jour/article/view/1551
https://doi.org/10.15690/vramn1551